Methods of Treating Heart Failure by Administration of Omecamtiv Mecarbil - Patent application
Patent Information
- Application Number
- JP2023528276
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-07-22
- Filing Date
- 2021-11-11
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-11-11
AI Technical Summary
【0222】 主要アウトカムに対するオメカムチブメカルビルを用いる処置の有益な効果は、主に心不全イベントの大幅な低減により引き起こされ、駆出率は、この治療効果の重要な変更因子であった(駆出率四分位による交互作用p=0.004、連続変数としての駆出率による交互作用p=0.001;表7)。駆出率は、オメカムチブメカルビルによる心不全入院の漸進的低減に対し同様の変更効果を示した(駆出率四分位による交互作用p=0.004、連続変数としての駆出率による交互作用p=0.001;図11A;表7)。主要複合エンドポイントと一致して、心不全による入院の発生率は、プラセボ及びオメカムチブメカルビルで処置された患者の両方で駆出率が減少するのに伴い増加する(図11B)が、オメカムチブメカルビルを用いる処置により影響を大きく受け、駆出率の減少に伴い、絶対差が徐々に大きく低減することを示した。駆出率は、同様に、全心不全イベント及び入院に対しオメカムチブメカルビルの効果の処置を大幅に変更した(それぞれ、交互作用p=0.006及び0.009;表20)。オメカムチブメカルビルは、集団全体においても、ベースラインの駆出率の関数としても、心血管死に対し全体的な影響を及ぼさなかった(駆出率四分位による交互作用p=0.14;図12A、表7)。予想通り、心血管死の発生率は、駆出率の減少に伴い、プラセボ群及びオメカムチブメカルビル群の両方で同等に増加した(図12B、表7)。同様に、全死因死亡率に対するオメカムチブメカルビルの影響はなかった(表7)。シェーンフェルド残差の検定により、表2に提示された全てのハザード比について、比例ハザードの推定を評価した。重大な違反は、検出されなかった(全てp>0.2)。
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 112,995, filed November 12, 2020, U.S. Provisional Patent Application No. 63 / 154,077, filed February 26, 2021, U.S. Provisional Patent Application No. 63 / 187,084, filed May 11, 2021, U.S. Provisional Patent Application No. 63 / 202,873, filed June 28, 2021, and U.S. Provisional Patent Application No. 63 / 203,436, filed July 22, 2021, the disclosures of which are incorporated by reference in their entireties herein. [Background technology]
[0002] Cardiomyonemes are the basic units of cardiac muscle contraction. They are highly ordered cytoskeletal structures composed of cardiac myosin, actin, and a series of regulatory proteins. The discovery and development of small molecule cardiac myosin activators will lead to promising treatments for acute and chronic heart failure. Cardiac myosin is a cytoskeletal motor protein of cardiomyocytes. It is directly involved in the conversion of chemical energy into mechanical force, which causes myocardial contraction.
[0003] Current positive inotropic drugs, such as beta-adrenergic receptor agonists or inhibitors of phosphodiesterase activity, increase the concentration of intracellular calcium, thereby increasing the contractility of myocardial segments. However, increasing calcium levels increases the rate of myocardial contraction and shortens the systolic ejection time, which is associated with potentially life-threatening side effects. In contrast, cardiac myosin activators function by a mechanism that directly stimulates the activity of cardiac myosin motor proteins without increasing intracellular calcium concentrations. They accelerate the rate-limiting step of the myosin enzyme cycle, shifting it to favor a force-producing state. Rather than increasing the rate of cardiac contraction, this mechanism instead lengthens the systolic ejection time, thereby increasing myocardial contractility and cardiac output in a potentially oxygen-efficient manner.
[0004] Heart failure with reduced ejection fraction is characterized by reduced contractile function leading to reduced cardiac output and increased filling pressures. To date, no drugs that directly address contractile function have improved outcomes. Cardiac myosin activators are a class of myotropes that improve myocardial function by directly enhancing myocardial nodal function. Omecamtiv mecarbil enhances cardiac contractility by selectively binding to cardiac myosin and increasing the number of force generators (myosin heads), which bind to actin filaments and can perform the power stroke once the cardiac cycle begins. In early clinical studies using short-term intravenous administration, omecamtiv mecarbil improved cardiac function. In patients with chronic heart failure with reduced ejection fraction, treatment with omecamtiv mecarbil for 20 weeks increased left ventricular systolic function and reduced left ventricular systolic and diastolic volumes, suggesting beneficial reverse cardiac remodeling, and reduced natriuretic peptide concentrations and heart rate.
[0005] No. 7,507,735 (hereby incorporated by reference) discloses a genus of compounds including omecamtivmecarbil (AMG423, CK-1827452), which has the following structure: [ka]
[0006] Omecamtiv mecarbil (OM) is the first in a class of direct activators of cardiac myosin that directly targets the contractile machinery of cardiomyocytes with the intention of increasing the efficiency of myocardial contraction in patients suffering from cardiovascular conditions such as heart failure.
[0007] Many treatments have been developed to improve cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, none of the currently available drugs directly improve the reduced systolic function, the central defect in HFrEF. Furthermore, severe impairment of systolic function is often associated with reduced blood pressure and great difficulty in tolerating guideline-based target doses of medical therapy. Myotropes are a new class of drugs that improve myocardial function by directly enhancing myocardial nodal function. Omecamtiv mecarbil, a cardiac myosin activator, is the first of this class and selectively promotes actin-myosin interactions, thereby increasing contractile function and contractile force without altering calcium transients in cardiomyocytes.
[0008] Despite significant improvements in prognosis with modern medical therapy, HF with reduced ejection fraction (HFrEF) remains a progressive clinical syndrome, and many patients deteriorate over time despite optimal guideline-based treatment. Various names are used to describe such patients, including “advanced HF,” “severe HF,” “refractory HF,” or “Stage D HF.” Regardless of the terminology, these patients have a high symptom burden, repeated HF hospitalizations, high mortality, and account for a large proportion of the total cost of HF care. As HF progresses, many patients are increasingly unable to tolerate neurohormonal blockade with beta-blockers or renin-angiotensin-aldosterone system (RAAS) modulators due to hypotension or renal insufficiency, limiting medical treatment options. Selected patients with progressive HF may be candidates for other treatments, such as heart transplant or mechanical cardiac support, but these treatments are costly, invasive, and of limited availability. Intravenous inotropic therapy can be used to alleviate symptoms in selected patients, but may be associated with increased mortality. Thus, there is a clear unmet need for effective, safe, long-term medical treatments for patients with more advanced stage HF.
[0009] Identifying safe drugs that improve cardiac function has been a goal of heart failure treatment for over a century, yet those developed consistently increase the incidence of myocardial ischemia, ventricular arrhythmias, or death through mechanisms that increase intracellular calcium transients. As a selective cardiac myosin activator, omecamtiv mecarbil has been shown to have no effect on these transients.
[0010] Despite previous developments in this field, there remains a need to treat heart failure in patients. Summary of the Invention [Means for solving the problem]
[0011] Provided herein is a method of treating heart failure in a patient having a left ventricular ejection fraction (LVEF) of less than 35% (e.g., less than 30%, less than 28%, less than 25%, or less than 22%) comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0012] Also provided herein is a method of treating heart failure in a patient not exhibiting atrial fibrillation or atrial flutter, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0013] Also provided herein is a method of treating heart failure in a patient with heart failure classified as Class III or IV as determined using the New York Heart Association (NYHA) classification, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0014] Also provided herein is a method of treating heart failure in a patient with advanced heart failure comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0015] The present disclosure further provides a method of treating ischemic heart failure in a patient, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0016] Also provided herein is a method for treating heart failure in a patient with myocardial infarction comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0017] Also provided herein is a method of treating heart failure in a patient having an NT-proBNP level of at least 2,000 pg / mL prior to initiation of omecamtiv mecarbir treatment, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbir as described herein.
[0018] Also described herein are methods for treating heart failure in a patient suffering from hypotension, symptomatic hypotension, renal impairment, or bradycardia, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0019] Also provided herein is a method of treating heart failure in a patient who is unable to tolerate one or more of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, diuretics, aldosterone antagonists, inotropes, neprilysin inhibitors, digitalis, and digoxin, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0020] Also provided herein is a method for preventing stroke in a patient suffering from heart failure with reduced ejection fraction (HFrEF), comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein. [Brief description of the drawings]
[0021] [Figure 1A] The primary endpoint in the evaluated patient population is shown. The primary endpoint was a composite of time to heart failure events or cardiovascular death, whichever occurred first. [Figure 1B] The incidence of cardiovascular death in the evaluated patient population is shown. [Figure 1C] 1 shows the incidence of heart failure events in the patient population evaluated. [Figure 1D]The incidence of all-cause mortality in the patient population evaluated is shown. [Figure 2A] The primary outcome of the study will be a composite of heart failure events or cardiovascular death according to subgroups prespecified in the protocol. Race was self-reported by patients. Baseline NT-proBNP subgroups will exclude subjects with atrial fibrillation / flutter at screening. [Figure 2B] The primary outcome of the study will be a composite of heart failure events or cardiovascular death according to subgroups prespecified in the protocol. Race was self-reported by patients. Baseline NT-proBNP subgroups will exclude subjects with atrial fibrillation / flutter at screening. [Figure 2C] The primary outcome of the study will be a composite of heart failure events or cardiovascular death according to subgroups prespecified in the protocol. Race was self-reported by patients. Baseline NT-proBNP subgroups will exclude subjects with atrial fibrillation / flutter at screening. [Diagram 3] 1 illustrates the propagation approach to multiplicity testing. [Figure 4] 1 shows the clinical trial design of omecamtiv mecarbir. [Diagram 5] 1 shows the powder X-ray diffraction pattern (XRPD) of omecamtiv mecarbil dihydrochloride monohydrate Form A. [Figure 6] 1 shows XRPD of omecamtiv mecarbil dihydrochloride hydrate salt forms, including Form B, at various temperatures. [Figure 7] 1 shows the XRPD of omecamtiv mecarbil dihydrochloride hydrate salt forms, including Form C, at various relative humidity conditions. [Figure 8A] The primary composite endpoint (PCE) showed progressively greater improvements with decreasing left ventricular ejection fraction (LVEF), as indicated by the continuing improvement in hazard ratios. [Figure 8B]Compared to placebo (stars), the incidence of the primary composite endpoint (PCE) increased with decreasing ejection fraction (EF), and omecamtiv mecarbil (circles) demonstrated a greater absolute reduction in PCE with decreasing EF. [Figure 9] Analysis of ejection fraction (EF) as a continuous variable shows that the treatment effect of omecamtivmecarbil increases progressively with decreasing EF (interaction effect, p=0.004). [Figure 10A] The difference in the incidence of the primary composite endpoint was shown to increase disproportionately between the placebo (stars) and omecamtiv mecarbil (circles) treatment groups with low ejection fraction. [Figure 10B] Results show that the absolute risk reduction with omecamtiv mecarbil increased gradually with decreasing ejection fraction (EF). [Figure 11A] We show that the beneficial impact of treatment with omecamtiv mecarbir on the primary outcome was primarily driven by a significant reduction in heart failure events.
[0022] [Figure 11B] The incidence of heart failure hospitalization was shown to increase with decreasing ejection fraction in both placebo (stars) and omecamtiv mecarbil (circles) treated patients, but was significantly affected by treatment with omecamtiv mecarbil, showing gradually greater reductions in absolute differences with decreasing ejection fraction. [Figure 12A] We show that OM had no overall effect on cardiovascular mortality in the overall population or as a function of baseline ejection fraction (EF). [Figure 12B] OM shows that the incidence of cardiovascular death increased similarly in both the placebo group (stars) and the omecamtiv mecarbil group (circles) with decreasing ejection fraction (EF). [Figure 13A] 1 shows the distribution of baseline ejection fraction in GALACTIC-HF. [Figure 13B] The distribution of ejection fraction in GALACTIC-HF is shown. [Figure 14A]For each endpoint (CV death or HF event), Kaplan-Meier curves are shown comparing patients with more advanced heart failure (HF) with those without. [Figure 14B] For each endpoint (CV death), Kaplan-Meier curves are shown comparing patients with more advanced heart failure (HF) with those without. [Figure 15A] Event rates for the primary endpoint by treatment assignment and advanced heart failure (HF) criteria met (specific advanced HF criteria) are shown. [Figure 15B] Event rates for the primary endpoint are shown by treatment assignment and advanced heart failure (HF) criteria met (total number of advanced HF criteria met). [Figure 16A] Outcomes by baseline NT-proBNP (primary composite outcome) in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline) are shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 16B] Outcome (HF hospitalization) by baseline NT-proBNP in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline) is shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 16C] Outcome (CV death) by baseline NT-proBNP in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline) is shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 16D] Outcomes (all-cause mortality) according to baseline NT-proBNP in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline) are shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 17A] Baseline NT-proBNP outcomes (primary composite outcome) are shown in the pre-specified analysis population of all randomized patients (placebo - stars; omecamtiv mecarbil - pills). [Figure 17B]Outcome (HF hospitalization) by baseline NT-proBNP in the pre-specified analysis population of all randomized patients is shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 17C] Outcome (CV death) by baseline NT-proBNP in the pre-specified analysis population of all randomized patients is shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 17D] Outcomes (all-cause mortality) by baseline NT-proBNP in the prespecified analysis population of all randomized patients are shown (placebo - stars; omecamtiv mecarbil - pills). [Figure 18A] Shown are the effects of randomized treatment on outcomes by baseline NT-proBNP concentration (presented as continuous measurements) (primary composite outcome) in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline). [Figure 18B] Shown is the effect of randomized treatment on outcome (HF hospitalization) by baseline NT-proBNP concentration (shown as continuous measurements) in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline). [Figure 18C] Shown is the effect of randomized treatment on outcome (CV death) by baseline NT-proBNP concentration (shown as continuous measurements) in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline). [Figure 18D] Shown is the effect of randomized treatment on outcome (all-cause mortality) according to baseline NT-proBNP concentrations (presented as continuous measurements) in the randomized pre-specified analysis population (no atrial fibrillation / flutter at baseline). [Figure 19A] The effect of randomized treatment on outcomes by baseline NT-proBNP concentration (presented as continuous measurements) (primary composite outcome) in a pre-specified analysis population in all randomized patients is shown. [Figure 19B]Shows the effect of randomized treatment on outcome (HF hospitalization) by baseline NT-proBNP concentration (presented as continuous measurements) in a pre-specified analysis population in all randomized patients. [Figure 19C] The effect of randomized treatment on outcome (CV death) by baseline NT-proBNP concentration (presented as continuous measurements) in a pre-specified analysis population in all randomized patients is shown. [Figure 19D] The effect of randomized treatment on the outcome (all-cause mortality) according to baseline NT-proBNP concentrations (presented as continuous measurements) in a pre-specified analysis population in all randomized patients is shown. [Figure 20A] Shows the effect of omecamtiv mecarbil compared with placebo on NT-proBNP after randomization in the pre-specified analysis population (no atrial fibrillation / flutter at baseline, all NT-proBNP concentrations). [Figure 20B] Show the effect of omecamtiv mecarbil compared with placebo on NT-proBNP after randomization in the pre-specified analysis population (no atrial fibrillation / flutter at baseline, NT-proBNP >median). [Figure 20C] Shows the effect of omecamtiv mecarbil compared with placebo on NT-proBNP after randomization in the pre-specified analysis population (no atrial fibrillation / flutter at baseline, NT-proBNP ≦median). [Figure 20D] FIG. 1 shows the effect of omecamtiv mecarbir compared to placebo on NT-proBNP in all randomized patients (total NT-proBNP concentrations). [Figure 20E] Figure 1 shows the effect of omecamtiv mecarbir compared to placebo on NT-proBNP in all randomized patients (NT-proBNP > median). [Figure 20F] FIG. 1 shows the effect of omecamtiv mecarbir compared to placebo on NT-proBNP in all randomized patients (NT-proBNP≦median). [Figure 21A] The proportion of patients with AFF as a function of the percentage of LVEF. [Figure 21B] 1 shows the effect of omecamtiv mecarbir in patients with or without AFF who received or did not receive digoxin. [Figure 21C] Figure 1 shows the effect of omecamtiv mecarbir on mortality in patients with or without AFF on mortality, cardiovascular or all-cause mortality, and heart failure hospitalization. [Figure 21D] The effect of omecamtiv mecarbir on mortality in patients with or without AFF (receiving or not receiving digoxin) on mortality, cardiovascular or all-cause mortality, and hospitalization for heart failure is shown. [Figure 21E] To demonstrate the effect of omecamtiv mecarbir in patients with AFF compared to placebo on the occurrence of serious adverse events. [Figure 21F] The arithmetic mean pharmacokinetic concentration-time profiles for administration of digoxin alone and digoxin with omecamtiv mecarbir are shown. [Figure 21G] Geometric mean pharmacokinetic parameters for administration of digoxin alone and digoxin with omecamtiv mecarbir are shown. [Figure 22] Kaplan-Meier curves for the primary composite endpoint by EF quartiles are shown. [Figure 23A] Outcomes by baseline systolic blood pressure (SBP) (primary composite outcome) are shown for all randomized patients (placebo - stars; omecamtiv mecarbil - pills). [Figure 23B] To demonstrate the treatment effect of omecamtiv mecarbil on the primary composite outcome by baseline systolic blood pressure (SBP). [Figure 24] Stroke incidence (fatal and non-fatal stroke events) for all randomized patients is shown. [Diagram 25]The effect of treatment with omecamtiv mecarbil compared to placebo on the incidence of stroke (fatal and non-fatal stroke events) in patients with or without a history of stroke is shown (placebo - stars; omecamtiv mecarbil - circles). [Figure 26] The effect of treatment with omecamtiv mecarbil compared to placebo on the incidence of stroke (fatal and non-fatal stroke events) in patients with or without a history of atrial fibrillation (placebo - stars; omecamtiv mecarbil - circles). [Figure 27] To demonstrate the effect of treatment with omecamtiv mecarbir in patients without atrial fibrillation / atrial flutter (AFF) at screening and in patients with no history of AFF compared with placebo on the occurrence of new-onset AFF (placebo - stars; omecamtiv mecarbir - circles). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] The present disclosure provides a method for treating heart failure in a patient, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.In various cases, the method disclosed herein includes treating heart failure in a patient with other cardiovascular conditions, for example, a patient with a left ventricular ejection fraction (LVEF) of less than 28%, a patient without atrial fibrillation or atrial flutter, a patient with heart failure classified as class III or IV as determined by the New York Heart Association classification, a patient with ischemic heart failure, a patient with myocardial infarction, a patient with NT-proBNP level above the median, or a patient with reduced ejection fraction (HFrEF).
[0024] The present disclosure provides a method for treating patients with heart failure and reduced ejection fraction who undergo guideline-based medical and device therapy. Furthermore, the disclosed method provides a statistically significant reduction in the primary composite outcome risk of heart failure events or death from cardiovascular causes. This effect is evident after about 3 months of treatment and persists for a period of time (e.g., 3 years after treatment) without evidence of increased risk of myocardial ischemic events, ventricular arrhythmias, or cardiovascular or all-cause mortality. As described herein, patients who undergo the methods disclosed herein may show a reduction in NT-proBNP levels compared to placebo.
[0025] Patients treated with the disclosed methods demonstrated similar rates of myocardial ischemia, ventricular arrhythmias, and mortality between treatment groups over approximately 7,500 patient-years of follow-up, suggesting that treatment with omecamtiv mecarbir does not increase the risk of these adverse clinical effects. Combined with the lack of adverse effects on blood pressure, heart rate, creatinine, or potassium levels, this supports the finding that selective targeting of myocardial nodes with omecamtiv mecarbir is a safe approach to improving cardiac function.
[0026] As used herein, "treatment" or "treating" refers to any treatment of a disease in a patient, including: a) preventing the disease, i.e., not allowing the clinical symptoms of the disease to progress; b) inhibiting the disease; c) slowing or arresting the progression of clinical symptoms; and / or d) alleviating the disease, i.e., causing regression of clinical symptoms. Treatment of diseases and disorders herein is also intended to include prophylactic treatment, e.g., prophylactically administering a pharmaceutical formulation described herein to a subject (i.e., an animal, preferably a mammal, most preferably a human) believed to be in need of chronic heart failure.
[0027] As used herein, the term "therapeutically effective amount" means an amount that is effective to treat a disease when administered to a human or non-human patient, e.g., a therapeutically effective amount can be an amount sufficient to treat a disease or disorder responsive to myosin activation. A therapeutically effective amount can be ascertained experimentally, e.g., by assaying blood concentrations of a chemical entity, or theoretically by calculating bioavailability.
[0028] Patient population The present disclosure provides a method for treating heart failure in patients in need of such treatment. The disclosed method provides a reduction in the composite of heart failure events or cardiovascular death without evidence of adverse safety signals in a wide range of patients, including those with moderate to severe heart failure symptoms and those with low ejection fraction, systolic blood pressure and renal function. In various cases, heart failure patients show an 8% overall risk reduction when administered omecamtiv mecarbil disclosed herein compared to placebo controls.
[0029] In some embodiments, treating heart failure in a patient in need thereof may result in reduced risk of heart failure hospitalization and / or cardiovascular death, as well as other benefits including reduced heart rate, stroke, and / or natriuretic peptide concentrations.
[0030] In another aspect, the present disclosure also provides a method of reducing heart rate, reducing stroke risk, reducing risk of heart failure hospitalization, reducing risk of cardiovascular death, and / or reducing / decreasing natriuretic peptide concentrations (e.g., NT-proBNP levels) in a heart failure patient.
[0031] Although multiple drugs have been developed to improve inotropy, omecamtiv mecarbil is the first drug to specifically increase contractile function by targeting the sarcomere without any direct vascular, electrophysiological, or neurohormonal effects and without increasing mortality. It exerts this effect by selectively binding to myosin and stabilizing its lever arm in a primed position, resulting in the accumulation of cardiac myosin heads in a pre-power stroke state before the onset of cardiac contraction. This mechanism increases the number of power generators (myosin heads) that can bind to actin filaments and perform the power stroke when the cardiac cycle begins, without altering calcium transients in the cardiomyocyte.
[0032] Furthermore, treatment with omecamtiv mecarbil was associated with a greater reduction in heart failure events in patients with low baseline ejection fraction. Combined with the higher risk of heart failure events in these patients, patients treated with omecamtiv mecarbil showed a greater relative treatment effect and a smaller absolute risk reduction for the primary composite endpoint of heart failure events and cardiovascular death in those with low baseline ejection fraction. These findings support the concept that certain subpopulations of heart failure patients, such as those with more severe heart failure, may derive greater clinical benefit from cardiac myosin activator therapy.
[0033] Patients with Left Ventricular Ejection Fraction (LVEF) Less than 35%: In some cases, the heart failure patient is one that also exhibits a lower ejection fraction (ejection fraction ≦35%) prior to the initiation of omecamtiv mecarbil treatment as described herein. In some embodiments, in conjunction with the above or below embodiments, the patient's left ventricular ejection is ≦35% (e.g., less than), ≦30% (e.g., less than), ≦28% (e.g., less than), ≦25% (e.g., less than), or ≦22% (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 22%, 23 ... %, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%. In some embodiments, in conjunction with any of the above or below embodiments, the patient's left ventricular ejection is 22% or less, 28% or less, or between 23% and 28%.
[0034] Reduced ejection fraction may correlate with other patient characteristics. In large clinical trials, patients with low ejection fraction, when assessed by quartiles, were more likely to be younger, male, and non-white, less likely to be enrolled in Eastern Europe or Russia, and more likely to be enrolled in the United States, Canada, Western Europe, South Africa, or Australia. Patients with low ejection fraction were more likely to have a non-ischemic etiology of heart failure, NYHA III / IV functional class, lower body mass index, lower systolic blood pressure, higher heart rate, higher NT-proBNP, and higher cardiac troponin I, and less likely to have coronary artery disease, hypertension, type 2 diabetes, or atrial fibrillation / flutter. Reduced ejection fraction was associated with increased symptom burden (lower KCCQ-TSS) in patients enrolled as inpatients, but not in outpatients. Patients with low ejection fraction had more use of ARNi, ivabradine, digitalis glycosides, cardiac resynchronization therapy, and implantable cardioverter defibrillators compared with patients with high ejection fraction. Thus, in any of the embodiments provided herein, the patient may have one or more of the characteristics described above.
[0035] In one aspect, provided herein is a method for treating heart failure in a patient with heart failure who also exhibits a reduced ejection fraction. In some embodiments, provided herein is a method for treating heart failure in a patient with heart failure who also exhibits a reduced ejection fraction by administering omecamtiv mecarbil, where the administration results in, for example, a reduced risk of occurrence or time to heart failure events or cardiovascular death. In a large clinical trial, selectively increasing systolic function in HFrEF patients improved cardiovascular outcomes, primarily through a reduction in heart failure events (primary composite endpoint: HR, 0.92; p=0.025). Omecamtiv mecarbil provided incremental benefits by reducing heart failure events in patients with low baseline ejection fraction. As a result, patients with ejection fractions below the median (≦28%) experienced a 16% reduction in the primary endpoint. Patients in the lowest quartile of ejection fraction had a relative risk reduction of 17% and an absolute risk reduction of 7.4 events / 100 patient-years (3-year NNT=11.8) for the primary composite endpoint.
[0036] In some embodiments, treating patients with low ejection fraction is effective in providing risk reduction compared to placebo. Risk reduction can be a relative risk reduction and / or absolute risk reduction. In some embodiments, risk reduction is measured as event rate / 100 patient years. The event can be a first heart failure event or cardiovascular death. In various cases, patients with LVEF of 28% or less have a 16% reduction in time to first heart failure event or cardiovascular death. In some embodiments, risk reduction can be an absolute risk reduction and / or a relative risk reduction in patients with EF less than about 28% or less than about 22%. In some embodiments, the absolute risk reduction is at least about 5 events / 100 patient years (e.g., 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5 events / 100 patient years). In some embodiments, the absolute risk reduction is about 7.4 events / 100 patient years. In some embodiments, the treatment is effective to result in a relative risk reduction of at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 15%.
[0037] In some embodiments, the relative risk reduction is 17%. In some embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18% , 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%. In certain embodiments, the patient's LVEF is 28% or less (e.g., less than). In certain embodiments, the patient's LVEF is 22% or less (e.g., less than).
[0038] In some embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, Methods are provided for reducing the number or frequency of heart failure events (e.g., heart failure hospitalizations) in patients with LVEF of 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% or less. In certain embodiments, the LVEF of the patient is 28% or less (e.g., less). In certain embodiments, the LVEF of the patient is 22% or less (e.g., less). In some embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19% , 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%. In certain embodiments, the patient's LVEF is 28% or less (e.g., less than). In certain embodiments, the patient's LVEF is 22% or less (e.g., less than).
[0039] It has also been observed that patients with low ejection fractions exhibit greater reductions in NT-proBNP upon treatment with omecamtiv mecarbil. In a large clinical trial, administration of omecamtiv mecarbil resulted in greater reductions in NT-proBNP, reduced ejection fraction, and a 22% reduction in NT-proBNP in the lowest EF quartile (≦22%) at 24 weeks. Thus, it is herein understood that administration of omecamtiv mecarbil results in a reduction in NT-proBNP levels in patients with LVEF of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) compared to baseline (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 26%, 27 ... %, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%. In certain embodiments, the LVEF of the patient is 28% or less (e.g., less than). In certain embodiments, the LVEF of the patient is 22% or less (e.g., less than). In some such embodiments, the patient's NT-proBNP levels are reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.In some embodiments, left ventricular ejection is 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% or less). or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% of patients) have NT-proBNP levels reduced to less than 2500, 2400, 2300, 2200, 2100, 2000, 1900, 1800, 1700, 1600, or 1500 pg / ml. In some embodiments, the reduction in NT-proBNP occurs over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 36, or 48 weeks.
[0040] In other embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 22% or less). %, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% of patients. In some embodiments, the left ventricular ejection is 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, if or less than 10% or any of 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% of patients have a reduction in NT-proBNP level of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.In some embodiments, left ventricular ejection is 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% or less). or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10% of patients) have NT-proBNP levels reduced to less than 2500, 2400, 2300, 2200, 2100, 2000, 1900, 1800, 1700, 1600, or 1500 pg / ml. In some embodiments, the reduction in NT-proBNP occurs over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 36, or 48 weeks. In some embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, In one embodiment, a method is provided for decreasing NT-proBNP in a patient in which the NT-proBNP level is 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or is less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%.
[0041] In a large-scale clinical trial, no significant effects on systolic blood pressure, serum potassium, or creatine were observed across quartiles of ejection fraction with omecamtiv mecarbil compared to placebo. Also, no significant differences were observed in the incidence of most adverse events between omecamtiv mecarbil and placebo treatment groups. However, in particular, the incidence of adjudicated stroke was clearly reduced in patients treated with omecamtiv mecarbil. Thus, in some embodiments, a method for reducing stroke risk in patients with heart failure (e.g., HFrEF) is provided, comprising administering omecamtiv mecarbil as described herein.
[0042] In other embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, , 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, and administering omecamtiv mecarbil reduces the stroke risk of the patient compared to a placebo. In some embodiments, a method of inhibiting or reducing the stroke risk of a patient with heart failure (e.g., HFrEF) is provided. In some embodiments, the patient's LVEF is 35% or less (e.g., less). In certain embodiments, the patient's LVEF is 28% or less (e.g., less). In certain embodiments, the patient's LVEF is 22% or less (e.g., less). In some embodiments, the risk reduction can be an absolute risk reduction and / or a relative risk reduction. In some embodiments, the risk reduction is a relative reduction in stroke risk compared to placebo. In some such embodiments, the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, where the patient's LVEF is equal to or less than 35% (e.g., less than), the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, or 25%. In other embodiments, where the patient's LVEF is equal to or less than 28% (e.g., less than), the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45%.In some embodiments where the patient's LVEF is equal to or less than 22% (e.g., less than), the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, or 35%. In some embodiments, with the embodiments above or below, the stroke is fatal. In some embodiments, with the embodiments above or below, the stroke is non-fatal. In some embodiments, with the embodiments above or below, the stroke is ischemic or non-hemorrhagic. In some embodiments, with the embodiments above or below, the stroke is ischemic with hemorrhagic transformation. In some embodiments, with the embodiments above or below, the stroke is hemorrhagic. In some embodiments, with the embodiments above or below, the patient does not have a history of stroke. In some embodiments, with the embodiments above or below, the patient does not have a history of atrial fibrillation. In some embodiments, with the embodiments above or below, the patient has a history of atrial fibrillation. In some embodiments, with the above or below embodiments, the patient is free of atrial fibrillation / flutter upon the first administration of omecamtiv mecarbil.In some embodiments, with the above or below embodiments, the patient is free of atrial fibrillation / flutter.
[0043] In a large clinical trial, omecamtiv mecarbil did not adversely affect blood pressure, heart rate, potassium homeostasis, or renal function when assessed by ejection fraction quartile. A small reduction in heart rate, thought to be secondary to sympathetic withdrawal, was consistently observed across ejection fraction groups.
[0044] In some embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 19%, 20%, 22%, 23 ... 8%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, wherein administration reduces the heart rate. In some embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) compared to placebo (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, Provided herein is a method of reducing the heart rate of a patient with heart failure (LVEF is 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or is less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%). In some embodiments, the patient's LVEF is 35% or less (e.g., less than). In certain embodiments, the patient's LVEF is 28% or less (e.g., less than). In certain embodiments, the patient's LVEF is 22% or less (e.g., less than). In some embodiments, the reduction in heart rate is about 1, 2, 3, 4, or 5 beats per minute (bpm). In certain embodiments, the reduction in heart rate is about 1-5, 1-4, 1-3, 1-2, 2-5, 2-4, 2-4, 3-5, 3-4, or 4-5 bpm.In yet another embodiment, the reduction in heart rate is a reduction of about 1-2 bpm.
[0045] In some embodiments, administration of omecamtiv mecarbil as described herein results in a reduction in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 19%, 20%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 32%, 33%, 34 ... Provided herein is a method of treating heart failure in a patient with heart failure where the risk of stroke is less than 6%, 15%, 14%, 13%, 12%, 11%, or 10%, or less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, wherein administration reduces the risk of stroke. In certain embodiments, administration of omecamtiv mecarbil as described herein results in left ventricular ejection of 35% or less (e.g., less than), 30% or less (e.g., less than), 28% or less (e.g., less than), 25% or less (e.g., less than), or 22% or less (e.g., less than) compared to placebo (e.g., 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, Provided herein are methods of reducing stroke risk in a patient with heart failure (LVEF is 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%, or is less than 34%, 33%, 32%, 31%, 30%, 29%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, or 10%). In some embodiments, the patient's LVEF is 35% or less (e.g., less). In certain embodiments, the patient's LVEF is 28% or less (e.g., less). In certain embodiments, the patient's LVEF is 22% or less (e.g., less). In some embodiments, the risk reduction can be an absolute risk reduction and / or a relative risk reduction. In some embodiments, the risk reduction is a relative reduction in stroke risk compared to placebo.In some such embodiments, the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments where the patient's LVEF is 35% or less (e.g., less), the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, or 25%. In other embodiments where the patient's LVEF is 28% or less (e.g., less), the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 45%. In some embodiments where the patient's LVEF is 22% or less (e.g., less), the patient's relative risk of stroke is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, or 35%.
[0046] Patients who do not exhibit atrial fibrillation or atrial flutter (AFF): As is understood, atrial fibrillation and atrial flutter are types of tachyarrhythmia, where atrial fibrillation manifests as a rapid and disorganized beating of the atria, and atrial flutter results in a rapid but regular beat. Atrial fibrillation and atrial flutter can be diagnosed using any suitable method (e.g., electrocardiogram, echocardiogram, transesophageal echocardiogram, chest x-ray, MRI scan, CT scan, exercise stress test, etc.). In some embodiments, in conjunction with the above or below embodiments, the heart failure patient does not exhibit atrial fibrillation or atrial flutter before the initiation of omecamtiv mecarbil treatment as described herein.
[0047] In one aspect, provided herein is a method of treating heart failure in a heart failure patient not exhibiting AFF. In some embodiments, the heart failure patient does not exhibit AFF. In some embodiments, the patient without AFF is administered digoxin. In some embodiments, the patient without AFF is not administered digoxin. In some embodiments, treatment of a patient without AFF by administration of omecamtiv mecarbil is effective to provide a risk reduction compared to placebo. The risk reduction can be a relative risk reduction and / or an absolute risk reduction. In some embodiments, the risk reduction is measured as an event rate / 100 patient years. The event can be a first heart failure event or cardiovascular death. In some embodiments, the risk reduction can be an absolute risk reduction and / or a relative risk reduction in a heart failure patient not exhibiting AFF. In some embodiments, the treatment is effective to provide a relative risk reduction of at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%. In some embodiments, treatment with omecamtiv mecarbil reduces the risk of cardiovascular death and / or heart failure events (e.g., heart failure hospitalization) in patients without AFF. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in patients without AFF. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalization) in patients without AFF. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of vascular death in patients without AFF.
[0048] In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in heart failure patients not exhibiting AFF. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalizations) in heart failure patients not exhibiting AFF. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in heart failure patients not exhibiting AFF. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of all-cause mortality in heart failure patients not exhibiting AFF. In some embodiments, the relative risk reduction is at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%.
[0049] In some embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in a heart failure patient without AFF (patient is not receiving digoxin). In some embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalizations) in a heart failure patient without AFF (patient is not receiving digoxin). In other embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in a heart failure patient without AFF (patient is not receiving digoxin). In other embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of all-cause mortality in a heart failure patient without AFF (patient is not receiving digoxin). In some embodiments, the relative risk reduction in heart failure patients without AFF (not receiving digoxin) is at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%.
[0050] In other embodiments, provided herein is a method of reducing the time to first heart failure event in a heart failure patient without AFF (the patient is receiving digoxin) by administration of omecamtiv mecarbil as described herein. In some embodiments, provided herein is a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalizations) in a heart failure patient without AFF (the patient is receiving digoxin) by administration of omecamtiv mecarbil as described herein. In other embodiments, provided herein is a method of reducing the risk of cardiovascular death in a heart failure patient without AFF (the patient is receiving digoxin) by administration of omecamtiv mecarbil as described herein. In other embodiments, provided herein is a method of reducing the risk of all-cause mortality in a heart failure patient without AFF (the patient is receiving digoxin) by administration of omecamtiv mecarbil as described herein. In some embodiments, the relative risk reduction in heart failure patients without AFF (not receiving digoxin) is at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%. In still other embodiments, it is 20%. In some embodiments, the relative risk reduction is 22%. In still other embodiments, the relative risk reduction is 25%.
[0051] Patients exhibiting atrial fibrillation or atrial flutter (AFF): Treatment with omecamtiv mecarbir may reduce the occurrence of serious adverse events in patients with AFF. In some aspects, provided herein is a method of reducing the risk of serious adverse events in heart failure patients with AFF (patients receiving digoxin) by administration of omecamtiv mecarbir as described herein. In some embodiments, treatment is effective to provide a relative risk reduction of at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 15%.
[0052] Heart failure patients classified as class III or IV: The New York Heart Association (NYHA) classification is a paradigm that describes patients suffering from heart failure, where patients are classified into one of four categories based on the degree to which they are limited during physical activity. Class I patients have no limitations during physical activity, i.e., normal physical activity does not cause excessive fatigue, palpitations, or shortness of breath. Class II patients are only slightly limited during physical activity, such that normal physical activity results in fatigue, palpitations, or shortness of breath. Class III patients suffer from significant limitations during physical activity, and fatigue, palpitations, or shortness of breath are caused even when activity is less than normal. Class IV heart failure patients experience symptoms of heart failure at rest and are unable to continue physical activity without increasing discomfort. In some embodiments, in conjunction with the above or following embodiments, heart failure patients are classified as class III or IV as determined using the New York Heart Association (NYHA) classification.
[0053] Patients with More Advanced Heart Failure (HF): In some aspects, methods of treating patients with more advanced HF by administration of omecamtiv mecarbil as described herein are provided. More advanced HF, also referred to as severe heart failure, refractory heart failure, or stage D heart failure, can be determined based on a number of criteria recognized in the medical field. In some embodiments, more advanced HF refers to the published criteria of the 2018 ESC-HFA Position Statement (European journal of heart failure. 2018;20:1505-1535). In the ESC-HFA criteria, patients were required to have all of the following: 1) NYHA class III-IV symptoms; 2) left ventricular ejection fraction ≦30%; 3) ≥2 HF hospitalizations within the past 12 months; and 4) evidence of severe functional impairment as defined by cardiopulmonary exercise test or 6-minute walk test. In some embodiments, the hospitalization criteria is modified to 1 HF hospitalization within the past 6 months. In some embodiments, more advanced HF refers to patients with all of the following: 1) NYHA Class III-IV symptoms, 2) left ventricular ejection fraction ≦30%, and 3) one or more hospitalizations for HF within the past 6 months.
[0054] On the other hand, true end-stage HF patients who may require mechanical support, heart transplantation, or hospice care, referred to as stage D patients in the AHA / ACC guidelines, represent a very small percentage of the HF population (approximately 2% of the unselected community cohort). In some embodiments, the progressive HF patients described herein do not include true end-stage HF patients (referred to as stage D patients in the AHA / ACC guidelines) who may require mechanical support, heart transplantation, or hospice care. In yet other embodiments, progressive HF patients do not include patients who require IV inotropic therapy or mechanical ventilation or circulatory support. A much larger population of ambulatory HF patients have severe symptoms, severe cardiac dysfunction, and frequent hospitalizations, but do not yet require progressive HF treatments such as mechanical support or heart transplantation. In some embodiments, progressive heart failure patients include patients who have severe symptoms, severe cardiac dysfunction, and frequent hospitalizations, but do not yet require progressive HF treatments, such as mechanical support or heart transplantation. In some embodiments, patients with progressing HF as described herein may include those with NYHA class III-IV, ejection fraction ≦30%, and HF hospitalization within the past 6 months.
[0055] In some embodiments, the patient undergoing treatment suffers from heart failure classified as class III or IV as determined using the NYHA classification. In some embodiments, the patient's LVEF is less than 30% (e.g., 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, and 1%). In some embodiments, the patient is hospitalized with heart failure or has been hospitalized with heart failure one or more times (e.g., 1, 2, 3, 4, 5 times, etc.) within 6 months prior to treatment. In some embodiments, the patient suffers from severe functional impairment as defined by cardiopulmonary exercise test or 6-minute walk test. In some embodiments, patients meet one or more of the following: 1) NYHA Class III-IV symptoms, 2) left ventricular ejection fraction < 30%, 3) one or more hospitalizations for HF within the past 6 months (including those hospitalized at the time of study enrollment), and 4) evidence of severe impairment as defined by cardiopulmonary exercise testing or 6-minute walk test. In some embodiments, patients meet all of the following: 1) NYHA Class III-IV symptoms, 2) left ventricular ejection fraction < 30%, 3) one or more hospitalizations for HF within the past 6 months (including those hospitalized at the time of study enrollment), and 4) evidence of severe impairment as defined by cardiopulmonary exercise testing or 6-minute walk test. In some embodiments, patients meet one or more of the following: 1) NYHA Class III-IV symptoms, 2) left ventricular ejection fraction < 30%, and 3) one or more hospitalizations for HF within the past 6 months. In some embodiments, the patient meets all of the following: 1) NYHA Class III-IV symptoms, 2) left ventricular ejection fraction < 30%, and 3) one or more HF hospitalizations within the past 6 months.
[0056] Despite significant improvements in medical treatment of HFrEF, patients with more advanced HF still experience high symptom burden, frequent HF hospitalizations, and high mortality. As HF worsens, the economic cost of care increases dramatically, and these patients account for a disproportionate share of HF costs. Often, as HF progresses, pathological symptoms of severe systolic dysfunction and low cardiac output, including hypotension and progressive renal failure, begin to predominate. These features progressively limit the ability to tolerate guideline-recommended HF treatments, e.g., beta-blockers, RAAS modulators, or mineralocorticoid receptor antagonists, resulting in a mismatch between patient risk and the intensity of medical treatment. Omecamtiv mecarbil differs from other HF treatments in that it directly targets systolic function rather than modulating associated neurohormonal derangements. Unlike other HFrEF treatments, omecamtiv mecarbil does not lower blood pressure, affect renal function, or alter potassium homeostasis, allowing its use even in patients with cardiorenal limitations to other HF treatments. In a large clinical trial, in patients classified as having advanced HF, there were no significant differences in systolic blood pressure, serum creatinine, or serum potassium at 24 weeks between patients treated with omecamtiv mecarbir or placebo. These data support both the efficacy and tolerability of omecamtiv mecarbir in a patient population that is difficult to treat effectively with other HF medications.
[0057] In patients with more advanced HF, as defined by NYHA class, EF, and recent HF hospitalization, omecamtiv mecarbir treatment resulted in a clinically significant reduction in the composite of HF hospitalization and cardiovascular death. These data support a possible role for omecamtiv mecarbir in patients with limited current treatment options.
[0058] In a large clinical trial, treatment with omecamtiv mecarbil led to clinically important improvements in outcomes in patients who met accepted definitions of advanced HF, such as one or more of the following: 1) NYHA class III-IV symptoms, 2) left ventricular ejection fraction ≤ 30%, 3) one or more hospitalizations for HF within the past 6 months (including those hospitalized at the time of study enrollment), and 4) evidence of severe functional impairment as defined by cardiopulmonary exercise testing or a 6-minute walk test. Given the high baseline risk in patients with more advanced HF, a relative risk reduction of 20% translated into a significant absolute risk reduction of 8.3 events / 100 patient-years (NNT=12) for the primary endpoint of time to first HF event or death from cardiovascular causes.
[0059] In some embodiments, treatment of patients with more advanced HF with omecamtiv mecarbil is effective in producing risk reduction compared to placebo. In some embodiments, the risk reduction is an absolute risk reduction. In some embodiments, the risk reduction is a relative risk reduction of about 20% (e.g., 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, etc.). For example, the absolute risk reduction can be at least 2 events / 100 patient-years (e.g., 3, 4, 5, 6, 7, 8, 9, 10 events / 100 patient-years). In some embodiments, the absolute risk reduction is about 8 events / 100 patient-years (e.g., 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9 events / 100 patient-years). In some embodiments, treatment of more advanced HF patients does not show a significant increase in serious adverse events occurring during treatment. In some embodiments, treatment of more advanced HF patients does not show a significant increase in serious adverse events related to ventricular tachyarrhythmia. In some embodiments, treatment with omecamtiv mecarbil reduces the risk of cardiovascular death and / or heart failure events (e.g., heart failure hospitalization) in more advanced HF patients. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in advanced heart failure patients. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalization) in more advanced heart failure patients. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in more advanced HF patients.
[0060] In more advanced HF populations, treatment with omecamtivmecarbil has been observed to be associated with a significant reduction in NT-proBNP. In some embodiments, NT-proBNP levels are reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% in more advanced HF patients. In some embodiments, NT-proBNP levels are reduced to less than 2500, 2400, 2300, 2200, 2100, 2000, 1900, 1800, 1700, 1600, or 1500 pg / ml in more advanced HF patients. In some embodiments, the reduction in NT-proBNP occurs over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 36, or 48 weeks. In some embodiments, administration of omecamtiv mecarbir as described herein provides a method of decreasing NT-proBNP in patients with more advanced HF.
[0061] Patients suffering from ischemic heart failure: In some embodiments, in conjunction with the above or following embodiments, the heart failure patient exhibits ischemic heart failure. As will be understood, ischemic heart failure refers to heart failure characterized by insufficient blood supply and oxygen delivery to tissues due to narrowing of arteries, for example, due to blood clots or vasoconstriction (e.g., plaque buildup). Ischemic heart disease, also known as coronary heart disease (CHD), can be diagnosed in several ways. For example, patients who have had a documented (previous) myocardial infarction or coronary revascularization (either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery) suffer from CHD. Furthermore, the presence of typical angina suggests a clinical diagnosis of CHD, but in most cases requires confirmation by additional diagnostic tests, such as coronary angiography.
[0062] Myocardial infarction patient: As understood, myocardial infarction or heart attack occurs when blood flow to the heart is blocked. Usually, the blockage is due to arterial plaque in the coronary artery. Any suitable method (e.g., electrocardiogram, blood test, chest x-ray, electrocardiogram, angiogram, cardiac CT or MRI, etc.) can be used to diagnose myocardial infarction or damage caused thereby. In some embodiments, in conjunction with the above or below embodiments, the heart failure patient also suffers from myocardial infarction.
[0063] Patients with reduced ejection fraction: In some embodiments, in conjunction with the above or below embodiments, the heart failure patient also has reduced ejection fraction (HFrEF). As will be appreciated, HFrEF is characterized by a decrease in the pumping power of the left ventricle such that the ejection fraction is 40% or less (normal ejection fraction is greater than 55%). In some cases of HFrEF, the left ventricle is enlarged and therefore unable to pump normally. In other cases, HFrEF can be caused by coronary heart disease, heart attack, cardiomyopathy, hypertension, aortic stenosis, mitral regurgitation, viral myocarditis, and / or arrhythmia.
[0064] Additionally, it is understood that a patient's risk of stroke increases with a decrease in ejection fraction. Accordingly, the disclosed method provides a method of inhibiting or reducing the risk of stroke in a patient suffering from HFrEF, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil as described herein.
[0065] Patients with pre-treatment levels of NT-proBNP of at least 2000 pg / mL: In some embodiments, the administration of omecamtiv mecarbil as described herein provides a method for treating heart failure patients with elevated NT-proBNP levels. NT-proBNP levels are understood to be a marker of heart failure (e.g., higher levels indicate progression of heart failure). Patients with very high natriuretic peptide levels are particularly at high risk and often have other clinical features, such as hypotension and inadequate renal function, that cause intolerance to some recommended treatments. Additional treatment options are attractive for these individuals, and in many cases, inotropic treatment is accompanied by mechanical support or even the use of transplantation. Omecamtiv mecarbil may be one of such treatment possibilities. In populations with higher baseline NT-proBNP levels, omecamtiv mecarbil has been found to provide higher treatment efficacy. In contrast, another new treatment, vericiguat, reduced treatment efficacy at higher NT-proBNP concentrations. Plasma natriuretic peptide concentrations reflect ventricular wall stress, blood volume, cardiac rhythm, and renal function. Thus, in HFrEF patients, natriuretic peptides provide an integrated measure of cardiac preload and afterload, atrial size, wall thickness, and contractile function, as well as the systemic effects of pump dysfunction. Moreover, by reflecting multiple aspects of cardiac structure and physiology, natriuretic peptides provide a more complete assessment of cardiac function than left ventricular ejection fraction, the most widely used measure of contractile function. Thus, it is not surprising that selective targeting of myocardial nodes to improve pump function may be of most benefit to those with elevated NT-proBNP levels by identifying individuals with the greatest cardiac dysfunction.
[0066] In some embodiments, in conjunction with the above or below embodiments, the heart failure patient has an N-terminal prohormone B-type natriuretic peptide (BNP) (NT-proBNP) of at least 2000 pg / mL prior to initiation of omecamtiv mecarbil treatment as described herein. In some cases, the patient exhibits an NT-proBNP level of at least 2000 pg / mL. In some embodiments, the patient has a pre-treatment level of NT-proBNP of 2000-150,000 pg / mL. For example, in some cases, prior to omecamtiv mecarbil treatment as described herein, the patient's NT-proBNP level is 1,700, 1,800, 1,900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 1,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 2 6,000, 27,000, 28,000, 29,000, 30,000, 31,000, 32,000, 33,000, 34,000, 35,000, 36,000, 37,000, 38,000, 39,000, 40,000, 41,000, 42,000, 43,000, 44,000, 45,000, 46,000, 47,000, 48,000, 49,000, 5 0,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, 100,000, 105,000, 110,000, 115,000, 120,000, 125,000, 130,000, 135,000, 140,000, 145,000, or 150,000 pg / mL. Thus, pre-treatment patients may exhibit NT-proBNP levels limited to and including any of the above values.For example, in some cases, the patient has an NT-proBNP level of 2000-150,000 pg / mL, e.g., 2000-125,000 pg / mL, or 2500-150,000 pg / mL, or 3000-125,000 pg / mL, or 3000-100,000 pg / mL, prior to the omecamtiv mecarbil treatment described herein. In various cases, the disclosed methods reduce the patient's NT-proBNP level upon omecamtiv mecarbil treatment described herein. Any suitable method can be used to measure the level of NT-proBNP. In various cases, upon treatment with omecamtiv mecarbil disclosed herein, the patient's NT-proBNP level is reduced by at least 5%, or at least 10%, e.g., 5%-15%.
[0067] In patients without AF / F who had high NT-proBNP levels compared with low NT-proBNP levels at baseline, omecamtiv mecarbir reduced the risk of the primary endpoint to a greater extent. Omecamtiv mecarbir reduced both components of the primary endpoint in patients with high NT-proBNP levels. Omecamtiv mecarbir also reduced the risk of the primary endpoint in the overall patient population, but to a smaller extent compared with participants without AF / F.
[0068] In the patient population without AF / F, treatment with omecamtiv mecarbir resulted in a relative risk reduction of 18% (95% CI 10-27%) in the primary endpoint, with a somewhat greater reduction in heart failure hospitalization (21, 11-30%) than in cardiovascular mortality (13, 0-25%) in patients with baseline NT-proBNP greater than the median, with no benefit in patients with NT-proBNP below the median. Analyses investigating the effect of omecamtiv mecarbir using NT-proBNP as a continuous measure suggested a linear interaction, with the benefit of omecamtiv mecarbir increasing steadily as NT-proBNP levels increased. The favorable effect of omecamtiv mecarbir occurred at an NT-proBNP threshold of approximately 2,000 pg / mL and increased in size with increasing NT-proBNP levels over the remaining range of baseline values (up to approximately 20,000 pg / mL). The benefits of omecamtivmecarbil were consistent in both inpatient and outpatient settings.
[0069] The benefit of omecamtiv mecarbil in the entire study population was less than that seen in participants without AF / F. This reflects a weakened or absent effect of omecamtiv mecarbil in patients with AF / F (who account for 37% of patients with NT-proBNP levels above the median). The reason for the lack of benefit of omecamtiv mecarbil in patients with AF / F is not yet clear. However, atrial arrhythmias themselves elevate natriuretic peptides, and for a given natriuretic peptide level, patients with AF / F have less LV systolic dysfunction than patients in sinus rhythm. Thus, patients with AF / F may have “diminished” the prevalence of severe LV systolic dysfunction in the entire study population with NT-proBNP above the median compared with participants without AF / F who have NT-proBNP above the median. Just as natriuretic peptides increase with chamber dilation, elevated wall stress, and reduced systolic function, reversal of these abnormalities with effective treatment reduces natriuretic peptides.
[0070] In some embodiments, the patient undergoing treatment has a pre-treatment level of NT-proBNP of at least about 2,000 pg / ml (e.g., 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 7000, 8000, 9000, 10,000, 15,000, and 20,000 pg / ml). In some embodiments, the patient has a pre-treatment level of NT-proBNP of less than about 20,000 pg / ml. In some embodiments, the patient is free of AF / F. In some embodiments, treatment in patients free of AF / F is effective to achieve a risk reduction, the risk reduction being a relative risk reduction of about 18% (e.g., about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the patient undergoing treatment has a pre-treatment level of NT-proBNP of at least about 2,000 pg / ml (e.g., 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 7000, 8000, 9000, 10,000, 15,000, and 20,000 pg / ml). In some embodiments, the patient has a pre-treatment level of NT-proBNP of less than about 20,000 pg / ml. In some embodiments, the patient is free of AF / F. In some embodiments, treatment in patients free of AF / F is effective to achieve a risk reduction, the risk reduction being a relative risk reduction of about 18% (e.g., about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.).
[0071] In one aspect, provided herein is a method of treating heart failure in a heart failure patient free of atrial fibrillation or flutter (free of AFF) and exhibiting NT-proBNP levels of at least 2000 pg / mL by administering omecamtiv mecarbil. In some embodiments, treating a patient free of AFF by administering omecamtiv mecarbil is effective to provide a risk reduction compared to placebo. The risk reduction can be a relative risk reduction and / or an absolute risk reduction. In some embodiments, the risk reduction is measured as an event rate / 100 patient years. An event can be a first heart failure event or cardiovascular death. In some embodiments, the risk reduction can be an absolute risk reduction and / or a relative risk reduction in heart failure patients not exhibiting AFF. In some embodiments, the treatment is effective to provide a relative risk reduction of at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%. In some embodiments, treatment with omecamtiv mecarbil reduces the risk of cardiovascular death and / or heart failure events (e.g., heart failure hospitalization) in patients without AFF and exhibiting NT-proBNP levels of at least 2000 pg / mL. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in patients without AFF and exhibiting NT-proBNP levels of at least 2000 pg / mL. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalization) in patients without AFF and exhibiting NT-proBNP levels of at least 2000 pg / mL. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in patients without AFF and exhibiting NT-proBNP levels of at least 2000 pg / mL.
[0072] In some embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in heart failure patients without AFF who exhibit NT-proBNP levels of at least 2000 pg / mL. In some embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalizations) in heart failure patients without AFF who exhibit NT-proBNP levels of at least 2000 pg / mL. In some embodiments, the administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in heart failure patients without AFF who exhibit NT-proBNP levels of at least 2000 pg / mL. In some embodiments, the relative risk reduction is at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%.
[0073] It was also observed that patients without AFF showed greater reductions in NT-proBNP on treatment with omecamtiv mecarbil. In a large clinical trial, omecamtiv mecarbil also reduced NT-proBNP to a greater extent in patients with baseline NT-proBNP levels above the median compared to patients with baseline NT-proBNP levels below the median. In other words, baseline NT-proBNP concentrations identified patients (i.e., those with higher baseline levels) who were more likely to respond favorably to omecamtiv mecarbil, as seen with other treatments, and reductions in NT-proBNP appeared to represent a surrogate for the efficacy of omecamtiv mecarbil.
[0074] Thus, in one aspect, provided herein is a method of treating heart failure in patients who do not exhibit AFF and who exhibit higher NT-proBNP levels at baseline (e.g., patients who exhibit NT-proBNP levels of at least 2000 pg / mL) by administration of omecamtiv mecarbil as described herein, where administration reduces NT-proBNP levels compared to baseline. In another aspect, provided herein is a method of reducing NT-proBNP in heart failure patients who do not exhibit AFF and who exhibit higher NT-proBNP levels at baseline (e.g., patients who exhibit NT-proBNP levels of at least 2000 pg / mL) by administration of omecamtiv mecarbil as described herein. In one aspect, provided herein is a method of reducing NT-proBNP levels in heart failure patients without AFF who exhibit higher NT-proBNP levels at baseline (e.g., patients who exhibit NT-proBNP levels of at least 2000 pg / mL)
[0075] In some embodiments, NT-proBNP levels are reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% in patients without AFF who exhibit NT-proBNP levels of at least 2000 pg / mL at baseline. In some embodiments, NT-proBNP levels are reduced to less than 2500, 2400, 2300, 2200, 2100, 2000, 1900, 1800, 1700, 1600, or 1500 pg / ml in patients without AFF who exhibit NT-proBNP levels of at least 2000 pg / mL at baseline. In some embodiments, the reduction in NT-proBNP occurs over 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, 24, 36, or 48 weeks. In some embodiments, administration of omecamtiv mecarbir as described herein provides a method of decreasing NT-proBNP in patients without AFF who exhibit a baseline NT-proBNP level of at least 2000 pg / mL.
[0076] In patients with NT-proBNP levels higher than the median baseline, the reduction in NT-proBNP with omecamtiv mecarbir was approximately 17% compared with the placebo group. In a previous analysis of 18 therapeutic interventions for heart failure, a 17% reduction in natriuretic peptide concentrations was associated with an approximately 20% relative risk reduction in heart failure hospitalization and a 13% reduction in mortality, an estimate that is close to the actual reductions observed in large clinical trials of omecamtiv mecarbir.
[0077] In yet another aspect, provided herein is a method of treating heart failure in a patient free of AFF who exhibits a baseline NT-proBNP level of at least 2000 pg / mL by administration of omecamtiv mecarbil as described herein, where the administration reduces the risk of heart failure events or cardiovascular death and reduces the level of NT-proBNP compared to baseline. In yet another aspect, provided herein is a method of reducing the risk of heart failure events or cardiovascular death and reducing the level of NT-proBNP in a patient free of AFF who exhibits a baseline NT-proBNP level of at least 2000 pg / mL. In some embodiments, treatment with omecamtiv mecarbil reduces the risk of heart failure events or cardiovascular death and reduces the level of NT-proBNP. In some embodiments, the reduction in heart failure events or cardiovascular death risk is a relative risk reduction of about 20% (e.g., 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, etc.). In some embodiments, the reduction in NT-proBNP levels is at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% reduction. In other embodiments, NT-proBNP levels are reduced to less than 2500, 2400, 2300, 2200, 2100, 2000, 1900, 1800, 1700, 1600, or 1500 pg / mL. In certain embodiments, treatment with omecamtiv mecarbil reduces the risk of heart failure events or cardiovascular death with a relative risk reduction of about 20% (e.g., 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, etc.) and a reduction in NT-proBNP levels of at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%.In other specific embodiments, treatment with omecamtiv mecarbil reduces the risk of heart failure events or cardiovascular death with a relative risk reduction of about 20% (e.g., 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, etc.) and a reduction in NT-proBNP levels of 2500, 2400, 2300, 2200, 2100, 2000, 1900, 1800, 1700, 1600, or 1500 pg / mL.
[0078] Patients with baseline systolic blood pressure (SBP): In some embodiments, the administration of omecamtiv mecarbil described herein provides a method for treating heart failure patients with low systolic blood pressure (e.g., 100 mmHg or less). Typical HFrEF treatments are not well tolerated by patients with SBP of 100 mmHg or less without increased incidence of adverse events or worsening renal function. Additional treatment options are attractive for these individuals. Omecamtiv mecarbil may be one such treatment possibility. Omecamtiv mecarbil has been found to provide high therapeutic efficacy in populations with low baseline systolic blood pressure (e.g., 100 mmHg or less).
[0079] In some embodiments, the patient exhibits a baseline systolic blood pressure of about 120 mmHg or less, about 115 mmHg or less, about 110 mmHg or less, about 105 mmHg or less, about 100 mmHg or less, about 95 mmHg or less, about 90 mmHg or less, about 85 mmHg, and about 120 mmHg, or about 110 mmHg to about 100 mmHg. In some embodiments, the heart failure patient has a systolic blood pressure of 100 mmHg or less prior to initiation of the omecamtiv mecarbil treatment described herein. In certain embodiments, the heart failure patient exhibits a baseline systolic blood pressure of about 85 mmHg to about 100 mmHg, about 85 mmHg to about 95 mmHg, about 85 mmHg to about 90 mmHg, about 90 mmHg to about 100 mmHg, about 90 mmHg to about 95 mmHg, or about 95 mmHg to about 100 mmHg.
[0080] Omecamtiv mecarbil was observed to significantly reduce the risk of the primary endpoint in patients with low SBP, which shows a linear inverse correlation with baseline SBP. In some embodiments, patients undergoing treatment exhibit a baseline systolic blood pressure of about 100 mmHg or less, about 95 mmHg or less, about 90 mmHg or less, about 85 mmHg to about 100 mmHg, about 85 mmHg to about 95 mmHg, about 85 mmHg to about 90 mmHg, about 90 mmHg to about 100 mmHg, about 90 mmHg to about 95 mmHg, or about 95 mmHg to about 100 mmHg.
[0081] In some embodiments, the treatment is effective to achieve a risk reduction, the risk reduction being a relative risk reduction of about 18% (e.g., about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the patient undergoing treatment exhibits a baseline SBP of about 100 mmHg or less. In some embodiments, treatment of patients exhibiting a baseline SBP of about 100 mmHg or less is effective to achieve a risk reduction, the risk reduction being a relative risk reduction of about 18% (e.g., about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.).
[0082] In one aspect, provided herein is a method of treating heart failure in a heart failure patient exhibiting a baseline SBP of about 100 mmHg or less by administering omecamtiv mecarbil. In some embodiments, treating a patient exhibiting a baseline SBP of about 100 mmHg or less by administering omecamtiv mecarbil is effective to provide a risk reduction compared to placebo. The risk reduction can be a relative risk reduction and / or an absolute risk reduction. In some embodiments, the risk reduction is measured as an event rate / 100 patient years. The event can be a first heart failure event or cardiovascular death. In some embodiments, the risk reduction can be an absolute risk reduction and / or a relative risk reduction in a heart failure patient exhibiting a baseline SBP of about 100 mmHg or less. In some embodiments, the treatment is effective to provide a relative risk reduction of at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%. In some embodiments, treatment with omecamtiv mecarbil reduces the risk of cardiovascular death and / or heart failure events (e.g., heart failure hospitalization) in patients with a baseline SBP of about 100 mmHg or less. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in patients with a baseline SBP of about 100 mmHg or less. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalization) in patients with a baseline SBP of about 100 mmHg or less. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in patients with a baseline SBP of about 100 mmHg or less.
[0083] In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the time to first heart failure event in a heart failure patient with a baseline SBP of about 100 mmHg or less. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the number or frequency of heart failure events (e.g., heart failure hospitalizations) in a heart failure patient with a baseline SBP of about 100 mmHg or less. In some embodiments, administration of omecamtiv mecarbil as described herein provides a method of reducing the risk of cardiovascular death in a heart failure patient with a baseline SBP of about 100 mmHg or less. In some embodiments, the relative risk reduction is at least 10% (e.g., 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, etc.). In some embodiments, the relative risk reduction is 12%. In some embodiments, the relative risk reduction is 15%. In some embodiments, the relative risk reduction is 17%.
[0084] Patients who cannot tolerate other standard therapies: In some embodiments, with the above or following embodiments, heart failure patients are unable to tolerate other standard therapies. Exemplary standard therapies for treating heart failure include, for example, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, diuretics, aldosterone antagonists, inotropes, neprilysin inhibitors, digitalis, and / or digoxin. In some cases, these patients are unable to tolerate other standard therapies, for example, due to hypotension, symptomatic hypotension, renal dysfunction, or bradycardia. In some embodiments, the present disclosure provides a method for treating heart failure patients suffering from symptomatic hypotension, renal dysfunction, or bradycardia, comprising administering omecamtiv mecarbil as disclosed herein. Further, in some embodiments, the patient treated has not been previously treated with one or more of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, neprilysin inhibitors, digitalis, and / or digoxin.Further, in some embodiments, in conjunction with the above or below embodiments, the patient treated herein suffers from hypotension, symptomatic hypotension, renal impairment, and / or bradycardia.
[0085] In some cases, the heart failure patient has received or is receiving one or more additional therapies (e.g., antihypertensive drugs) and / or interventional strategies (e.g., implantable devices) at the time of omecamtiv mecarbil treatment. In some embodiments, with the above or below embodiments, the patient has received cardiac resynchronization therapy (CRT) prior to treatment. In some embodiments, with the above or below embodiments, the patient wears an implantable cardioverter defibrillator (ICD) device. In some cases, the patient is administered sacubitril / valsartan.
[0086] Chronic Heart Failure Patients: In some embodiments, administration of omecamtiv mecarbil or a hydrate, salt, or salt of the hydrate provides a method for reducing the risk of a heart failure event or the risk of death from cardiovascular causes in a heart failure patient, such as a chronic heart failure patient. Heart failure events include, but are not limited to, emergency department visits, emergency department visits, and hospitalizations due to worsening heart failure. In some embodiments, in conjunction with the above or below embodiments, a heart failure event is an emergency department visit, emergency department visit, or hospitalization due to worsening heart failure that leads to an escalation of treatment beyond a change in oral diuretic therapy.
[0087] In some embodiments, in conjunction with the above or below embodiments, the treatment is effective for reducing the risk of heart failure events in heart failure patients, such as chronic heart failure patients. In some embodiments, the chronic heart failure patient also has one or more of the following: reduced ejection fraction, LVEF less than 30%, LVEF less than 28%, LVEF less than 25%, LVEF less than 22%, advanced heart failure, heart failure classified as class III or IV as determined using NYHA classification, or at least one heart failure hospitalization within 6 months prior to treatment. In some embodiments, the heart failure patient, such as chronic heart failure patient, is an inpatient.
[0088] In some embodiments, in conjunction with the above or below embodiments, the treatment is effective in reducing the risk of death, such as fatal stroke, in a heart failure patient. In some embodiments, the treatment is effective in reducing the risk of fatal stroke or non-fatal stroke in a heart failure patient (e.g., a chronic heart failure patient).
[0089] Route of administration and dosage OM can be administered via any suitable route. In some embodiments, as with other embodiments described above or below, omecamtiv mecarbil is administered orally. In some embodiments, as with other embodiments described above or below, OM is administered as a tablet.
[0090] OM can be administered in any suitable amount. In some embodiments, together with other above or below embodiments, OM is administered in a dosage of 10 mg or more (e.g., 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, or 40 mg or more). Alternatively, or in addition, OM can be administered in a dosage of 75 mg or less (e.g., 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, or 45 mg or less).
[0091] It will be understood that the description herein of the amount of omecamtiv mecarbil, its pharma- ceutically acceptable salt, or its pharma- ceutically acceptable hydrate will relate to the salt or hydrate form of the active ingredient. The amount of omecamtiv mecarbil described herein refers to the amount (or equivalent amount) of omecamtiv mecarbil free base. For example, if a tablet formulation is indicated to contain 1 mg of omecamtiv mecarbil, the tablet formulation contains 1.22 mg of omecamtiv mecarbil dihydrochloride monohydrate (molecular weight (MW) 492.37 g / mol). This provides 1 mg of omecamtiv mecarbil (MW 401.43 g / mol).
[0092] The disclosed methods include administering OM using an appropriate dosing schedule (e.g., once a day or twice a day). In some embodiments, in conjunction with other embodiments above or below, OM is administered twice a day.
[0093] In some embodiments, OM is administered at a dosage of 25 mg twice daily, or 37.5 mg twice daily, or 50 mg twice daily, in conjunction with other embodiments above or below. Plasma concentrations of omecamtiv mecarbil are assessed after 2 weeks of treatment at a given dose, and the dose may be adjusted so that the patient is within the target plasma concentration range according to: 1) if plasma concentration is less than 300 ng / mL, then increase to a higher dose; 2) if plasma concentration is between 300 and 750 ng / mL, no change; and 3) if plasma concentration is greater than 750 ng / mL, then decrease to a lower dose (if starting dose of 25 mg BID exceeds 750 ng / mL, 25 mg QD may be appropriate). Plasma concentrations of omecamtiv mecarbil may be assessed about 12 hours after the last dose of omecamtiv mecarbil. In some embodiments, the target plasma concentration range of omecamtiv mecarbil is 300 ng / mL to 750 ng / mL.
[0094] Omecamtiv mecarbil is a CYP3A4 substrate. Concomitant use of strong CYP3A4 inhibitors such as ketoconazole, or regimens containing ritonavir or cobicistat, may increase omecamtiv mecarbil plasma concentrations. Concomitant use of strong CYP3A4 inducers such as rifampin or carbamazepine may decrease omecamtiv mecarbil plasma concentrations. Omecamtiv mecarbil plasma concentrations may be rechecked 2 weeks after initiation or discontinuation of a strong CYP3A4 inhibitor or inducer to assess whether a dose adjustment of omecamtiv mecarbil is necessary.
[0095] Omecamtiv mecarbil, its salts, hydrates, and polymorphs The omecamtiv mecarbil used in the disclosed methods can be formulated in any suitable pharmaceutical formulation, which may be present as a pharma- ceutically acceptable salt, hydrate, or salt hydrate form.
[0096] As used herein, the term "pharmaceutically acceptable salts" includes salts with inorganic acids, such as hydrochlorides, phosphates, diphosphates, sulfates, and the like, as well as salts with organic acids, such as malates, maleates, fumarates, tartrates, succinates, citrates, acetates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, and alkanoates, such as acetates, HOOC-(CH2) n -COOH (wherein n is 0-4), and the like. Those skilled in the art will recognize various synthetic methodologies that can be used to prepare non-toxic pharma-ceutically acceptable addition salts. In some embodiments, the pharma-ceutically acceptable salt is a dihydrochloride salt.
[0097] As used herein, the term "hydrate" refers to a chemical entity formed upon the interaction of water and a compound, including, for example, a hemihydrate, monohydrate, dihydrate, trihydrate, etc. In some embodiments, the omecamtiv mecarbil hydrate or salt thereof is omecamtiv mecarbil monohydrate or salt thereof. In some cases, omecamtiv mecarbil exists as omecamtiv mecarbil dihydrochloride monohydrate.
[0098] As used herein, the terms "crystalline form", "polymorph", and "novel form" may be used interchangeably herein and are meant to include all crystalline and amorphous forms of a compound, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, nonsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms, and mixtures thereof, unless a specific crystalline or amorphous form is referred to. In some embodiments, along with other above or below embodiments, the disclosed methods include administering omecamtiv mecarbil dihydrochloride monohydrate salt. In some embodiments, along with other above or below embodiments, the methods include administering omecamtiv mecarbil dihydrochloride hydrate Form A. In some embodiments, along with other above or below embodiments, omecamtiv mecarbil as used herein is a solvate.
[0099] Form A may be characterized by an X-ray powder diffraction (XRPD) pattern obtained as shown in WO2014 / 152270A1 with peaks at 6.6, 14.9, 20.1, 21.4, and 26.8±0.2 degrees 2θ using CuKα radiation. Optionally, Form A may be further characterized by an XRPD pattern with additional peaks at 8.4, 24.2, 26.0, 33.3±0.2 degrees 2θ using CuKα radiation. Optionally, Form A can be even further characterized by an XRPD pattern having additional peaks at 6.2, 9.7, 13.2, 14.3, 15.4, 16.3, 16.9, 18.9, 19.5, 20.7, 21.8, 22.8, 23.6, 25.1, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7±0.2 °2θ using CuKα radiation. In various cases, Form A can be characterized by an XRPD pattern using CuKα radiation having peaks at 6.2, 6.6, 8.4, 9.7, 13.2, 14.3, 14.9, 15.4, 16.3, 16.9, 18.9, 19.5, 20.1, 20.7, 21.4, 21.8, 22.8, 23.6, 24.3, 25.1, 26.0, 26.8, 27.3, 27.7, 28.4, 29.4, 30.2, 31.2, 31.5, 31.9, 33.3, 33.9, 34.5, 34.9, 36.1, 36.8, 37.7, 38.5, and 39.7±0.2 degrees 2θ. In some embodiments, Form A can be characterized by an X-ray powder diffraction pattern substantially as shown in Figure 5, where "substantially" means that the reported peaks may vary by ±0.2°. It is well known in the field of XRPD that the relative peak heights in a spectrum depend on many factors, such as sample preparation and instrument geometry, while the peak positions are relatively insensitive to experimental details.
[0100] In some embodiments, the omecamtiv mecarbil used in the described methods comprises omecamtiv mecarbil dihydrochloride Form B. In some embodiments, the omecamtiv mecarbil used in the described methods comprises omecamtiv mecarbil dihydrochloride Form C. The Form B and Form C polymorphs of omecamtiv mecarbil are metastable anhydrous dihydrochloride forms and can be formed under a variety of conditions and temperatures, as described in detail in WO2014 / 152270, the disclosure of which is incorporated by reference in its entirety.
[0101] Form B may be characterized by an XRPD pattern with peaks at 6.8, 8.8, 14.7, 17.7, and 22.3±0.2 degrees 2θ using CuKα radiation. Optionally, Form B may be further characterized by an XRPD pattern with additional peaks at 9.6, 13.5, 19.2, 26.2±0.2 degrees 2θ using CuKα radiation. Form B can be characterized by an XRPD pattern using CuKα radiation with peaks at 6.2, 6.8, 8.8, 9.6, 13.5, 14.4, 14.7, 15.4, 16.3, 17.0, 17.7, 18.3, 19.2, 19.9, 20.5, 20.8, 21.8, 22.3, 22.7, 23.0, 24.8, 25.1, 25.5, 26.2, 26.4, 26.8, 27.5, 28.5, 30.2, 30.6, 31.1, 31.5, 32.1, 32.7, 34.1, 34.4, 35.5, 35.9, 38.1, 38.9±0.2 degrees 2θ. In some embodiments, Form B can be characterized by an XRPD pattern substantially as shown in FIG. 6, where "substantially" means that the reported peaks may vary by ±0.2°.
[0102] Form C may be characterized by an XRPD pattern with peaks at 6.7, 14.8, 17.4, 20.6, and 26.2±0.2 degrees 2θ using CuKα radiation. Optionally, Form C may be further characterized by an XRPD pattern with additional peaks at 8.7, 22.0, 27.1, and 27.7±0.2 degrees 2θ using CuKα radiation. Form C can be characterized by an XRPD pattern using CuKα radiation with peaks at 6.2, 6.7, 8.7, 9.6, 13.5, 14.5, 14.8, 15.4, 16.4, 17.1, 17.4, 18.4, 19.3, 19.5, 19.9, 20.6, 20.8, 21.8, 22.0, 22.5, 22.8, 24.3, 24.7, 25.1, 25.6, 26.2, 26.5, 27.1, 27.3, 27.7, 28.5, 30.0, 30.5, 31.0, 31.5, 32.2, 32.8, 34.1, 35.2, 36.0, 36.9, and 38.8±0.2 degrees 2θ. In some embodiments, Form C can be characterized by an XRPD pattern substantially as shown in FIG. 7, where "substantially" means that the reported peaks may vary by ±0.2°.
[0103] Omecamtiv mecarbil preparation The disclosed methods include administering a therapeutically effective amount of omecamtiv mecarbil, or a pharma- ceutically acceptable salt, a pharma-ceutically acceptable hydrate, or a pharma-ceutically acceptable hydrate of a pharma-ceutically acceptable salt, such as omecamtiv mecarbil dihydrochloride monohydrate, in a suitable formulation.
[0104] Exemplary pharmaceutical formulations administered to patients in the methods disclosed herein include modified release matrix tablets that can uniformly release omecamtiv mecarbil at a pace controlled by the diffusion of omecamtiv mecarbil through a gel layer formed by hydration of the controlled release agent in the tablet. In some embodiments, as well as other above or below, the modified release matrix tablets exhibit minimal pH-dependent release in vitro. In some embodiments, as well as other above or below, complete release of omecamtiv mecarbil is achieved within 24 hours in both pH 2 and 6.8 dissolution media, likely reducing inter- and intra-subject variability and food effects. The modified release matrix tablet dosage form has been found to be superior to previous immediate release dosage forms in minimizing plasma peak-to-trough ratios. As a result, the modified release matrix tablets reduce plasma concentration fluctuations, leading to reduced side effects and improved safety and efficacy. The modified release matrix tablets are also expected to improve patient compliance by reducing dosing frequency. Additionally, the modified release matrix tablets are physicochemically stable, resulting in no changes in physical attributes, assays, impurities, or dissolution profiles after storage for 6 months at 40° C. / 75% RH. The modified release may be extended release in some embodiments.
[0105] In some embodiments, along with other above or below embodiments, the exposure of omecamtiv mecarbir 2-12 hours after administration to a human is 40-70 ng / mL. In some embodiments, along with other above or below embodiments, the exposure of omecamtiv mecarbir 2-12 hours after administration to a human is still 40-55 ng / mL.
[0106] In some embodiments, in conjunction with any other above or below embodiments, omecamtiv mecarbil is released at the following intervals: less than 30% of the dose dissolves in 1 hour; 30-75% of the dose dissolves in 3 hours; and greater than 80% of the dose dissolves in 12 hours.
[0107] In some embodiments, in conjunction with any other above or below embodiments, omecamtiv mecarbil is released at the following intervals: less than 30% of the dose dissolves in 2 hours; 30-75% of the dose dissolves in 6 hours; and greater than 80% of the dose dissolves in 16 hours.
[0108] Exemplary pharmaceutical formulations administered in the methods disclosed herein include omecamtiv mecarbil, or a pharma- ceutically acceptable salt, a pharma- ceutically acceptable hydrate, or a pharma- ceutically acceptable hydrate of a pharma- ceutically acceptable salt thereof; a controlled release agent; a pH adjusting agent; a filler; and a lubricant.
[0109] In some embodiments, omecamtiv mecarbil can be administered as a tablet.For example, tablet excipients can include one or more of fumaric acid, hypromellose, lactose monohydrate, microcrystalline cellulose, and magnesium stearate.The tablet can also include a film coating that can include one or more of polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
[0110] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 3-30% w / w omecamtiv mecarbil, or a pharma- ceutically acceptable salt, pharma-ceutically acceptable hydrate, or a pharma-ceutically acceptable hydrate of a pharma-ceutically acceptable salt thereof; 15-35% w / w of a controlled release agent; 20-45% w / w of a pH adjusting agent; 25-65% w / w of a filler; and 0.1-1.0% w / w of a lubricant.
[0111] In some embodiments, in conjunction with any of the other above or below embodiments, the pharmaceutical formulation administered comprises about 12-25 (w / w%) omecamtiv mecarbil di-HCl hydrate; 25-35 (w / w%) Methocel™ K100M Prem CR; 20-30 (w / w%) microcrystalline cellulose, PH102; 5-10 (w / w%) lactose monohydrate, FF316; 12-25 (w / w%) fumaric acid; 0.1-2 (w / w%) intragranular magnesium stearate; and 0.1-2 (w / w%) extragranular magnesium stearate. As used throughout this specification, Methocel™ K100M Prem CR is a hypromellose having a viscosity of 100,000 mPa·s at 2% concentration in water at 20° C.
[0112] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 3-10 (w / w%) omecamtiv mecarbil diHCl hydrate; 20-40 (w / w%) Methocel™ K100M Prem CR; 30-42 (w / w%) microcrystalline cellulose, PH102; 12-25 (w / w%) lactose monohydrate, FF316; 4-11 (w / w%) fumaric acid; 0.1-2 (w / w%) intragranular magnesium stearate; and 0.1-2 (w / w%) extragranular magnesium stearate.
[0113] In some embodiments, in conjunction with any of the other above or below embodiments, the pharmaceutical formulation administered comprises about 12-25 (w / w%) omecamtiv mecarbil di-HCl hydrate; 1-10 (w / w%) Methocel™ K100M Prem CR; 12-27 (w / w%) Methocel™ K100LV Prem CR; 20-35 (w / w%) microcrystalline cellulose, PH102; 4-15 (w / w%) lactose monohydrate, FF316; 12-25 (w / w%) fumaric acid; 0.1-2 (w / w%) intragranular magnesium stearate; and 0.1-2 (w / w%) extragranular magnesium stearate. As used throughout this specification, Methocel™ K100LV Prem CR is hypromellose having a viscosity of 100 mPa·s at 2% concentration in water at 20° C.
[0114] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered comprises about 3-10 (w / w%) omecamtiv mecarbil diHCl hydrate; 1-10 (w / w%) Methocel™ K100M Prem CR; 12-27 (w / w%) Methocel™ K100LV Prem CR; 30-50 (w / w%) microcrystalline cellulose, PH102; 15-25 (w / w%) lactose monohydrate, FF316; 3-11 (w / w%) fumaric acid; 0.1-2 (w / w%) intragranular magnesium stearate; and 0.1-2 (w / w%) extragranular magnesium stearate.
[0115] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 18-19 (w / w%) omecamtiv mecarbil diHCl hydrate 28-32 (w / w%) Methocel™ K100M Prem CR; 23-26 (w / w%) microcrystalline cellulose, PH102; 7-9 (w / w%) lactose monohydrate, FF316; 17-20 (w / w%) fumaric acid; 0.1-1 (w / w%) intragranular magnesium stearate; and 0.1-1 (w / w%) extragranular magnesium stearate.
[0116] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 5-7 (w / w%) omecamtiv mecarbil diHCl hydrate; 27-33 (w / w%) Methocel™ K100M Prem CR; 35-38 (w / w%) microcrystalline cellulose, PH102; 17-20 (w / w%) lactose monohydrate, FF316; 6-9 (w / w%) fumaric acid; 0.1-1 (w / w%) intragranular magnesium stearate; and 0.1-1 (w / w%) extragranular magnesium stearate.
[0117] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 17-20 (w / w%) omecamtiv mecarbil diHCl hydrate; 3-7 (w / w%) Methocel™ K100M Prem CR; 18-22 (w / w%) Methocel™ K100LV Prem CR; 26-30 (w / w%) microcrystalline cellulose, PH102; 8-11 (w / w%) lactose monohydrate, FF316; 17-20 (w / w%) fumaric acid; 0.1-1 (w / w%) intragranular magnesium stearate; and 0.1-1 (w / w%) extragranular magnesium stearate.
[0118] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 5-7 (w / w%) omecamtiv mecarbil diHCl hydrate; 3-7 (w / w%) Methocel™ K100M Prem CR; 18-22 (w / w%) Methocel™ K100LV Prem CR; 37-43 (w / w%) microcrystalline cellulose, PH102; 18-22 (w / w%) lactose monohydrate, FF316; 6-9 (w / w%) fumaric acid; 0.1-1 (w / w%) intragranular magnesium stearate; and 0.1-1 (w / w%) extragranular magnesium stearate.
[0119] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains approximately 18.37 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 24.20 (w / w%) microcrystalline cellulose, PH102; 8.07 (w / w%) lactose monohydrate, FF316; 18.37 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.5 (w / w%) extragranular magnesium stearate.
[0120] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 6.13 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 36.81 (w / w%) microcrystalline cellulose, PH102; 18.40 (w / w%) lactose monohydrate, FF316; 7.66 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.5 (w / w%) extragranular magnesium stearate.
[0121] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains approximately 18.37 (w / w%) omecamtiv mecarbil diHCl hydrate; 5 (w / w%) Methocel™ K100M Prem CR; 20 (w / w%) Methocel™ K100LV Prem CR; 27.95 (w / w%) microcrystalline cellulose, PH102; 9.31 (w / w%) lactose monohydrate, FF316; 18.37 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.5 (w / w%) extragranular magnesium stearate.
[0122] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 6.13 (w / w%) omecamtiv mecarbil diHCl hydrate; 5 (w / w%) Methocel™ K100M Prem CR; 20 (w / w%) Methocel™ K100LV Prem CR; 40.14 (w / w%) microcrystalline cellulose, PH102; 20.07 (w / w%) lactose monohydrate, FF316; 7.66 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.5 (w / w%) extragranular magnesium stearate.
[0123] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 6.13 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 27.94 (w / w%) microcrystalline cellulose, PH102; 27.94 (w / w%) lactose monohydrate, FF316; 6.74 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.75 (w / w%) extragranular magnesium stearate.
[0124] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 9.20 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 24.72 (w / w%) microcrystalline cellulose, PH102; 24.71 (w / w%) lactose monohydrate, FF316; 10.12 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.75 (w / w%) extragranular magnesium stearate.
[0125] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 12.27 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 21.49 (w / w%) microcrystalline cellulose, PH102; 21.49 (w / w%) lactose monohydrate, FF316; 13.50 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.75 (w / w%) extragranular magnesium stearate.
[0126] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 6.13 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 27.82 (w / w%) microcrystalline cellulose, PH102; 27.81 (w / w%) lactose monohydrate, FF316; 6.74 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 1.0 (w / w%) extragranular magnesium stearate.
[0127] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 9.20 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 24.59 (w / w%) microcrystalline cellulose, PH102; 24.59 (w / w%) lactose monohydrate, FF316; 10.12 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 1.0 (w / w%) extragranular magnesium stearate.
[0128] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 12.27 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 21.37 (w / w%) microcrystalline cellulose, PH102; 21.36 (w / w%) lactose monohydrate, FF316; 13.50 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 1.0 (w / w%) extragranular magnesium stearate.
[0129] In some embodiments, in conjunction with other above or below embodiments, the pharmaceutical formulation administered contains about 12.27 (w / w%) omecamtiv mecarbil diHCl hydrate; 30 (w / w%) Methocel™ K100M Prem CR; 31.04 (w / w%) microcrystalline cellulose, PH102; 10.35 (w / w%) lactose monohydrate, FF316; 15.34 (w / w%) fumaric acid; 0.5 (w / w%) intragranular magnesium stearate; and 0.5 (w / w%) extragranular magnesium stearate.
[0130] Combination treatment In some embodiments, in conjunction with the above or below embodiments, the disclosed method may include administering one or more additional therapeutic agents suitable for treating / ameliorating one or more cardiovascular conditions. In some embodiments, in conjunction with the above or below embodiments, the disclosed method includes administering to the patient a therapeutically effective amount of an angiotensin-converting enzyme (ACE) inhibitor. In some embodiments, in conjunction with the above or below embodiments, the disclosed method includes administering to the patient a therapeutically effective amount of a mineralocorticoid receptor antagonist (MRA).
[0131] In some cases, the ACE inhibitor comprises one or more agents selected from benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril.
[0132] In some cases, the MRA comprises one or more agents selected from spironolactone, eplerenone, canrenoic acid, canrenone, and drospirenone.
[0133] Embodiment
[0134] 1. A method for treating heart failure in a patient having a left ventricular ejection fraction (LVEF) of less than 35%, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0135] 2. The method of embodiment 1, wherein the patient's LVF is less than 30%.
[0136] 3. The method of embodiment 1, wherein the patient's LVF is less than 28%.
[0137] 4. The method of embodiment 1, wherein the patient's LVF is less than 25%.
[0138] 5. The method of embodiment 1, wherein the patient has an LVEF of less than 22%.
[0139] 6. A method for treating heart failure in a patient not exhibiting atrial fibrillation or atrial flutter comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0140] 7. The method of embodiment 6, wherein the patient's LVEF is less than 35%.
[0141] 8. The method of embodiment 6, wherein the patient's LVEF is less than 30%.
[0142] 9. The method of embodiment 6, wherein the patient's LVEF is less than 28%.
[0143] 10. The method of embodiment 6, wherein the patient's LVEF is less than 25%.
[0144] 11. The method of embodiment 6, wherein the patient's LVEF is less than 22%.
[0145] 12. A method for treating heart failure in a patient with heart failure classified as class III or IV as determined using the New York Heart Association (NYHA) classification, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0146] 13. A method of treating heart failure in a patient with advanced heart failure comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0147] 14. The method of embodiment 13, wherein the patient is suffering from heart failure classified as class III or IV as determined using the New York Heart Association (NYHA) classification.
[0148] 15. The method of embodiment 13 or 14, wherein the patient's LVEF is less than 30%.
[0149] 16. The method of any one of embodiments 13-15, wherein the patient has been hospitalized for heart failure at least once within 6 months prior to the treatment.
[0150] 17. The method of any one of embodiments 13-16, wherein the patient does not exhibit atrial fibrillation or atrial flutter.
[0151] 18. A method for treating ischemic heart failure in a patient comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0152] 19. A method for treating heart failure in a patient who has had a myocardial infarction comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0153] 20. A method of treating heart failure in a patient having a pre-treatment level of NT-proBNP of at least 2,000 pg / mL comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0154] 21. The method of embodiment 20, wherein the patient's LVEF is less than 35%.
[0155] 22. The method of embodiment 20, wherein the patient's LVEF is less than 30%.
[0156] 23. The method of embodiment 20, wherein the patient's LVEF is less than 28%.
[0157] 24. The method of embodiment 20, wherein the patient's LVEF is less than 25%.
[0158] 25. The method of embodiment 20, wherein the patient's LVEF is less than 22%.
[0159] 26. The method of any one of embodiments 20-25, wherein the patient does not exhibit atrial fibrillation or atrial flutter.
[0160] 27. A method for treating heart failure in a patient suffering from hypotension, symptomatic hypotension, renal dysfunction, or bradycardia comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0161] 28. The method of embodiment 27, wherein the patient has not been previously treated with one or more of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, diuretics, aldosterone antagonists, inotropes, neprilysin inhibitors, digitalis, and digoxin.
[0162] 29. A method for treating heart failure in a patient who is unable to tolerate one or more of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, diuretics, aldosterone antagonists, inotropes, neprilysin inhibitors, digitalis, and digoxin comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or a hydrate salt thereof.
[0163] 30. The method of embodiment 29, wherein the patient suffers from hypotension, symptomatic hypotension, renal dysfunction, or bradycardia.
[0164] 31. A method for preventing stroke in a patient suffering from heart failure with reduced ejection fraction (HFrEF), comprising administering to said patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0165] 32. The method of embodiment 31, wherein the stroke is non-fatal.
[0166] 33. The method of embodiment 31, wherein the stroke is fatal.
[0167] 34. The method of any one of embodiments 31-33, wherein the stroke is ischemic.
[0168] 35. The method of any one of embodiments 31-33, wherein the stroke is ischemic with hemorrhagic transformation.
[0169] 36. The method of any one of embodiments 31-33, wherein the stroke is hemorrhagic.
[0170] 37. A method for reducing the risk of heart failure events or death from cardiovascular causes in a patient with heart failure comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
[0171] 38. The method of embodiment 37, wherein the method reduces the patient's risk of a heart failure event.
[0172] 39. The method of embodiment 37 or 38, wherein the patient suffers from chronic heart failure with reduced ejection fraction.
[0173] 40. The method of any one of embodiments 37-39, wherein the heart failure event is an emergency department visit, an emergency department visit, or a hospitalization due to worsening heart failure that leads to an escalation of treatment beyond a change in oral diuretic therapy.
[0174] 41. The method of any one of embodiments 37-40, wherein the patient's LVEF is less than 30%.
[0175] 42. The method of any one of embodiments 37-40, wherein the patient's LVEF is less than 28%.
[0176] 43. The method of any one of embodiments 37-40, wherein the patient's LVEF is less than 25%.
[0177] 44. The method of any one of embodiments 37-40, wherein the patient's LVEF is less than 22%.
[0178] 45. The method of any one of embodiments 37-44, wherein the patient does not exhibit atrial fibrillation or atrial flutter.
[0179] 46. The method of any one of embodiments 37-45, wherein the patient suffers from advanced heart failure.
[0180] 47. The method according to any one of embodiments 37 to 46, wherein the patient suffers from heart failure classified as class III or IV as determined using the New York Heart Association (NYHA) classification.
[0181] 48. The method of any one of embodiments 37-47, wherein the patient has been hospitalized for heart failure at least once within 6 months prior to the treatment.
[0182] 49. The method of any one of embodiments 1-48, wherein the patient is an inpatient.
[0183] 50. The method of any one of embodiments 1-48, wherein the patient is an outpatient.
[0184] 51. The method of any one of embodiments 1-50, wherein the omecamtiv mecarbir is administered orally.
[0185] 52. The method of embodiment 51, wherein the omecamtiv mecarbir is administered in a tablet.
[0186] 53. The method of any one of embodiments 1-52, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbir dihydrochloride hydrate.
[0187] 54. The method of any one of embodiments 1-53, wherein the omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof, is administered in a modified release matrix tablet.
[0188] 55. The method of any one of embodiments 1-54, wherein the omecamtiv mecarbir is administered twice daily.
[0189] 56. The method of embodiment 55, wherein the omecamtiv mecarbir is administered in a dosage of 25 mg twice a day.
[0190] 57. The method of embodiment 55, wherein the omecamtiv mecarbir is administered at a dosage of 37.5 mg twice a day.
[0191] 58. The method of embodiment 55, wherein the omecamtiv mecarbir is administered in a dosage of 50 mg twice a day.
[0192] 59. The method of any one of embodiments 1-58, wherein the patient has undergone cardiac resynchronization therapy (CRT) prior to the procedure.
[0193] 60. The method of any one of embodiments 1-59, wherein the patient wears an implantable cardioverter defibrillator (ICD) device.
[0194] 61. The method of any one of embodiments 1-60, further comprising administering to the patient a therapeutically effective amount of an angiotensin-converting enzyme inhibitor.
[0195] 62. The method of any one of embodiments 1-61, further comprising administering to the patient a therapeutically effective amount of a mineralocorticoid receptor antagonist. EXAMPLES
[0196] The following examples further illustrate the disclosed methods of treatment but, of course, should not be construed as limiting their scope.
[0197] The following abbreviations are used in the examples: ACEi refers to angiotensin-converting enzyme inhibitors; ARB refers to angiotensin receptor blockers; ARNi refers to angiotensin receptor-neprilysin inhibitors; BB refers to beta-blockers; CRT refers to cardiac resynchronization therapy; ED refers to emergency department; eGFR refers to estimated glomerular filtration rate; HF refers to heart failure; hsTn refers to high-sensitivity troponin I; ICD refers to implantable cardioverter defibrillator; KCCQ refers to Kansas City Cardiomyopathy Questionnaire; LVEF refers to left ventricular ejection fraction; MAGGIC refers to the Meta-Analysis Global Group on Chronic HF; MRA refers to mineralocorticoid receptor antagonists; NEJM refers to the New England Journal of Medicine. Medicine; NT-proBNP refers to N-terminal pro B-type natriuretic peptide; NYHA refers to New York Heart Association; SBP refers to systolic blood pressure; SGLT2 refers to sodium-glucose cotransporter 2.
[0198] Study endpoint and event definitions were based on the ACC / AHA criteria for endpoint definition in cardiovascular clinical trials as described in: Hicks et al. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, J Am Coll Cardiol 2018;71:1021-34.
[0199] Patient Eligibility Patient eligibility requirements included age 18-85 years, New York Heart Association functional class (NYHA) II-IV symptoms, and ejection fraction ≤35%. Participants were currently hospitalized for heart failure (inpatient) or had either an emergency department visit or hospitalization for heart failure within the year prior to randomization (outpatient). Participants had N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations ≥400 pg / mL or BNP ≥125 pg / mL at screening (for atrial fibrillation / flutter: NT-proBNP ≥1,200 pg / mL or BNP ≥375 pg / mL). Patients were required to receive standard drug and device treatment for heart failure consistent with local clinical practice guidelines and optimized doses according to the investigator's judgment.
[0200] Major patient exclusion criteria included current hemodynamic or clinical instability requiring mechanical or intravenous medication, systolic blood pressure (SBP) less than 85 mmHg, and a blood pressure of 20 mL / min / 1.73 m 2 These conditions included an estimated glomerular filtration rate (eGFR) below 30%, recent acute coronary syndrome event, or cardiovascular surgery (including planned), and any other condition that would adversely affect study participation.
[0201] Study Procedure All eligible participants were randomized 1:1 to receive either placebo or omecamtiv mecarbir (pharmacokinetically guided doses: 25, 37.5, or 50 mg) orally twice daily. Predose plasma concentrations of omecamtiv mecarbir were measured at weeks 2 and 6, and the respective doses were adjusted at weeks 4 and 8. Patients and investigators were blinded to plasma concentrations and prescribed doses. A complete schedule of evaluations is presented in the protocol, available at NEJM.org. Study drug was temporarily withheld if a participant experienced clinical signs or symptoms consistent with acute myocardial infarction or ischemia.
[0202] Research results The primary outcome was a composite of time to heart failure event or cardiovascular death (whichever occurred first). Heart failure events were defined as emergency department visits, emergency department visits, or hospitalizations due to subjective and objective worsening of heart failure leading to treatment intensification beyond changes in oral diuretics. Secondary outcomes were: time to cardiovascular death; change in KCCQ Total Symptom Score (TSS) from baseline to week 24 (on a scale of 0 to 100; higher scores indicate fewer symptoms); time to first heart failure hospitalization; and time to all-cause death. All-cause mortality, HF events, major ischemic cardiac events (hospitalization for myocardial infarction / unstable angina, and coronary revascularization), and stroke were adjudicated by a blinded, external Clinical Events Committee (Duke Clinical Research Institute) using standardized definitions.
[0203] Summary of results Over a median time of 21.8 months, the primary outcome occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbir group and 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% CI, 0.86 to 0.99; P = .025); 808 patients (19.6%) who received omecamtiv mecarbir and 798 patients (19.4%) who received placebo died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11; P = .86); 1177 patients (28.6%) and 1236 patients (30.1%) experienced a first heart failure event (hazard ratio, 0.93; 95% CI, 0.87 to 0.99; P = .025). 1067 (25.9%) and 1065 (25.9%) died from any cause (hazard ratio, 1.00; 95% CI, 0.92 to 1.09). The frequency of cardiac ischemic and ventricular arrhythmic events did not differ between treatment groups.
[0204] Patients enrolled like patients were more symptomatic, as indicated by lower KCCQ total symptom scores at baseline; patients receiving omecamtiv mecarbir had a 2.5-point improvement in this score compared with placebo.
[0205] statistical analysis A sample size of approximately 8,000 patients was chosen to have 90% power to detect a hazard ratio for cardiovascular death of 0.8, assuming the following: cardiovascular death rate of 10% per year in the first year and 7% thereafter; enrollment period of 24 months; total study duration set at 48 months; time lag for subsequent treatments of 3 months, hazard ratio for treatment effect of 0.8; study drug discontinuation rate of 10% per year, and 10% of subjects failing to reach endpoint determination due to either noncardiovascular death or withdrawal from the study during the trial. The study was event-driven and terminated after approximately 1590 cardiovascular deaths. The overall type I error was 0.05 for two-sided tests across the primary and secondary endpoints with controls for multiple testing. A single interim efficacy analysis was performed after approximately two-thirds of the target number of cardiovascular deaths had occurred, with a one-sided alpha of 0.0005. Given the negligible impact of this interim measure on the final alpha, a maximum of 0.05 was used in the final analysis, consistent with the Haybittle-Peto approach. Efficacy analyses will be performed according to randomized treatment group assignment (intention to treat) on the complete analysis set including all randomized patients, except for 24 subjects from a single site who were excluded due to violations of the Standards for Clinical Trials of Pharmaceuticals. Time-to-event data were evaluated using Kaplan-Meier estimates and Cox proportional hazards models stratified by randomization setting and region, with treatment group and baseline eGFR as covariates. Mean differences in KCCQ TSS change from baseline to week 24 were estimated using mixed models stratified by randomization setting (inpatient and outpatient), containing baseline TSS value, region, baseline eGFR, routine visit, treatment group, and interactions of treatment group with routine visit. Joint omnibus F-tests were used to test the treatment effect of KCCQ TSS. An overall pooled estimate of the difference of KCCQ TSS treatment versus placebo will be performed using a likelihood-based approach. Pre-specified safety analyses included the following: adverse events associated with discontinuation of study treatment; "adverse events of interest", i.e., ventricular arrhythmias requiring treatment, and actively adjudicated major ischemic cardiac events (including myocardial infarction, hospitalization for unstable angina, and coronary revascularization).Safety analyses will be performed in patients who underwent randomization and received at least one dose of omecamtiv mecarbir or placebo (excluding 24 subjects as in the full analysis set). All analyses were performed using SAS software, version 9.4 (SAS Institute).
[0206] Enrollment, Randomization, Treatment, and Follow-up 8,256 participants were randomized, and 24 patients were excluded before the database was locked due to violations of the criteria for clinical trial conduct. Thus, 8,232 patients were included in the efficacy analysis. At the end of the study, the vital status of 16 patients was unknown (omecamtiv mecarbil: 9 patients withdrew consent; placebo: 6 patients withdrew consent and 1 was lost to follow-up). Baseline characteristics between the two treatment groups were balanced (Table 1). Overall median follow-up was 21.8 months (Q1, Q3; 15.4, 28.6 months). [Table 1-1] [Table 1-2] [Table 1-3]
[0207] Outcomes A first heart failure event or death from cardiovascular causes occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbir group and 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86, 0.99; P = .025; Figure 1A and Table 2). In the two components of this time-to-first-event composite, 1177 (28.6%) of patients receiving omecamtiv mecarbil and 1236 (30.1%) in the placebo group experienced a first heart failure event (hazard ratio, 0.93; 95% CI, 0.86 to 1.00; P = 0.063; Figure 1B and Table 2); death from cardiovascular causes contributed 346 events (8.4%) and 371 events (9.0%) (Table 2). The effect of omecamtiv mecarbil was generally consistent across most prespecified subgroups, with the statistically largest potential interaction observed in the ejection fraction subgroup (interaction effect p = 0.003; Figure 3).
[0208] The secondary outcome of time to death from cardiovascular causes occurred in 808 (19.6%) patients who received omecamtiv mecarbil and in 798 (19.4%) patients who received placebo (hazard ratio 1.01; 95% CI 0.92 to 1.11; P = 0.86; Figure 1C and Table 2). The prespecified analysis of change from baseline to week 24, improvement in KCCQ total symptom score, in the randomized setting (inpatients mean difference [95% CI]: 2.50 [0.54, 4.46], outpatients: -0.46 [-1.40, 0.48], joint p = 0.028) did not meet the threshold of p = 0.002 based on a multiple control testing procedure. Therefore, it and the other two secondary outcomes are considered exploratory. A first hospitalization for heart failure occurred in 1142 patients (27.7%) in the omecamtiv mecarbir group and 1179 patients (28.7%) in the placebo group (hazard ratio, 0.95; 95% CI, 0.87 to 1.03; Table 2), whereas death from any cause occurred in 1067 (25.9%) and 1065 (25.9%) patients, respectively (hazard ratio, 1.00; 95% CI, 0.92 to 1.09; Figure 1D and Table 2).
[0209] The Kaplan-Meier method was used to estimate the cumulative incidence of the primary outcome, heart failure events, death from cardiovascular causes, and death from any cause. Hazard ratios and 95% confidence intervals were estimated using Cox regression models stratified by site and region of randomization and treatment with omecamtiv mecarbil or placebo as explanatory variables. Analyses are based on all participants who underwent randomization. The insets in each panel of Figures 1A-1D show the same data on an expanded y-axis.
[0210] Other outcomes of interest included the effects of omecamtiv mecarbil on vital signs and selected laboratory values (Table 3). There were no significant differences in change in systolic blood pressure at 24 or 48 weeks between the omecamtiv mecarbil and placebo groups; there was a small but significant reduction in heart rate in participants assigned to omecamtiv mecarbil compared with placebo at both time points. Omecamtiv mecarbil significantly reduced NT-proBNP concentrations at week 24 compared with placebo. [Table 2]
[0211] NA indicates not applicable as P values for efficacy outcomes are reported only for outcomes that were included in the hierarchical trial strategy. *The primary outcome was a composite of heart failure events (hospitalization or emergency visit leading to intravenous treatment for heart failure) or death from cardiovascular causes. Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score ranged from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure. †Not significant. After statistical significance of the primary endpoint, CV death was tested against an alpha of 0.048 and change from baseline in KCCQ TSS was tested against an alpha of 0.002.
[0212] In addition, we analyzed the impact of LVEF on the treatment effect of omecamtiv mecarbil on cardiovascular outcomes. Data from the patient population showed that patients with a more significant reduction in ejection fraction were more likely to be younger, male, non-white, of American or Western European origin, and to have ischemic cardiomyopathy, normal sinus rhythm, and other clinical markers of more severe HFrEF compared to patients without a significant reduction in ejection fraction. There was significant heterogeneity in the effect of omecamtiv mecarbil on the primary composite endpoint with respect to LVEF (series interaction, p=0.002). Omecamtiv mecarbil gradually improved the primary composite endpoint with decreasing LVEF, as indicated by the successive improvement in the hazard ratio (Figure 8A). The incidence of PCE increased with decreasing EF, and omecamtiv mecarbil gradually improved the absolute reduction in PCE with decreasing EF (Figure 8B).
[0213] safety Excluding discontinuations due to death, 847 patients (20.6%) receiving omecamtiv mecarbir and 897 patients (21.9%) receiving placebo discontinued the study drug, and 371 patients (9.0%) in the omecamtiv mecarbir group and 382 patients (9.3%) receiving placebo discontinued due to adverse events. Patients receiving omecamtiv mecarbir had no changes in potassium or creatinine concentrations over the course of the study compared with placebo. Patients receiving omecamtiv mecarbir had a median increase in high-sensitivity troponin-I concentrations from baseline of 0.004 ng / mL at week 24 compared with placebo (lower limit of quantification, 0.010 ng / mL). A total of 200 participants (4.9%) receiving omecamtiv mecarbir had a positively adjudicated major ischemic cardiac event compared with a total of 188 (4.6%) receiving placebo, with myocardial infarction accounting for 122 (3.0%) and 118 (2.9%) of these events. Ventricular arrhythmias were similar in patients receiving omecamtiv mecarbir compared with placebo (Table 3). [Table 3-1] [Table 3-2]
[0214] Continuous variables were summarized as mean ± standard deviation (SD) or median and first and second quartiles (Q1, Q3), as appropriate. Categorical variables were summarized as numbers and percentages. The safety population included all patients who underwent randomization and received at least one dose of omecamtiv mecarbil or placebo. Change from baseline in NT-proBNP analysis included all participants who underwent randomization. Difference columns are exponential changes from baseline on a log scale using a mixed model including log baseline value, region, baseline eGFR, routine visit, treatment group, and interactions of treatment with routine visit.
[0215] Adverse Events Table 4 summarizes adverse events reported in ≥1% of patients. [Table 4]
[0216] Outcomes by ejection fraction Patient baseline characteristics were further assessed by EF quartiles. Continuous variables were summarized with mean and standard deviation or median and interquartile range, as appropriate. Categorical variables were summarized with number and percentage. Tests for trend across categories were performed with linear regression, Cuzick's nonparametric trend test, and chi-squared test for trend, respectively. Treatment effects on continuous outcomes were assessed via linear regression models adjusted for the corresponding baseline value of the parameter of interest. Survival analyses were performed using Poisson regression models to estimate incidence rates, rate differences, and rate ratios, and Cox proportional hazards models to estimate hazard ratios. Treatment effect hazard ratios were adjusted for eGFR and stratified by region and inpatient status, similar to the primary GALACTIC-HF analysis. Restricted cubic splines were utilized in Poisson regression models with 3 knots to allow for potentially nonlinear correlations between ejection fraction and time to event outcomes. All analyses were performed using STATA16 (College Station, TX). P values less than 0.05 were considered statistically significant. Due to the exploratory nature of these analyses, no adjustments for multiple comparisons were made.
[0217] Of the 8,232 participants analyzed, there were 4,456 patients with an EF of 28% or less (the median ejection fraction in the study) (Tables 5 and 6; Figures 13A and 13B). The method of measuring ejection fraction is shown in Table 19. [Table 5-1] [Table 5-2] [Table 5-3] [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5] [Table 7]
[0218] As we prioritized digits for ejection fraction assessment, more than 70% of patients had an EF of 30% or less. Assessed by quartiles, patients with low ejection fraction were more likely to be younger, male, and non-white, less likely to be enrolled in Eastern Europe or Russia, and more likely to be enrolled in the United States, Canada, Western Europe, South Africa, or Australia. Patients with low ejection fraction were more likely to have a non-ischemic etiology of heart failure, NYHA III / IV functional class, lower body mass index, lower systolic blood pressure, higher heart rate, elevated NT-proBNP, and elevated cardiac troponin I, and less likely to have coronary artery disease, hypertension, type 2 diabetes, or atrial fibrillation / flutter. Lower ejection fraction was associated with increased symptom burden (lower KCCQ-TSS) in patients enrolled as inpatients, but not significantly different in outpatients. There was no difference in the proportion of patients receiving triple therapy [(ACEi, ARB, or ARNi)+MRA+BB] among EF quartiles. Patients with low ejection fraction had more use of ARNi, ivabradine, digitalis glycosides, cardiac resynchronization therapy, and implantable cardioverter defibrillators compared with patients with high ejection fraction.
[0219] Relationship between ejection fraction and clinical outcomes Within the group of patients with HFrEF enrolled in GALACTIC-HF, the incidence of clinical outcomes increased with decreasing ejection fraction (Table 7). [Table 8-1] [Table 8-2]
[0220] As shown by placebo rates, the incidence of the primary outcome of first heart failure event or cardiovascular death in patients in the lowest EF quartile (EF ≤ 22%; 35.6 / 100 patient-years) was nearly 80% higher than in the highest EF quartile (EF ≥ 33%; 20 / 100 patient-years). Compared with the highest EF quartile, the incidence of first heart failure event was 90% higher (28.3 vs. 14.9 events / 100 patient-years) and the incidence of cardiovascular death was 68% higher (14.1 vs. 8.4 deaths / 100 patient-years) in the lowest EF quartile. Placebo participants had greater improvements in KCCQ-TSS at 24 weeks compared with baseline, and participants enrolled as hospitalized patients had greater improvements, but this effect was not modified by EF quartile (Table 8). [Table 9]
[0221] Effect of ejection fraction on the therapeutic efficacy of omecamtiv mecarbil Omecamtiv mecarbil significantly reduced the primary endpoint of time to first heart failure event or cardiovascular death in the overall study population (HR 0.92; p=0.025). The statistical analysis plan prespecified assessment of the primary endpoint in ejection fraction subgroups above or below the median (≤28%), and ejection fraction significantly modified the treatment effect of omecamtiv mecarbil (interaction effect, p=0.004). Patients with EF ≤28% had a 16% reduction in time to first heart failure event or cardiovascular death (HR 0.84, 95% CI 0.77-0.92; p=0.0003) compared with no difference in patients with EF >28% (HF 1.04, 95% CI 0.94-1.16; p=0.45). Analysis of the modification effect of treatment with omecamtiv mecarbil on the primary composite endpoint by quartiles of ejection fraction (interaction effect, p=0.013; Table 7, FIG. 22) showed a relative risk reduction of 15% and 17%, respectively, in the two lowest quartiles of ejection fraction. Analysis of ejection fraction as a continuous variable (interaction effect, p=0.004) showed that the treatment effect of omecamtiv mecarbil became progressively greater with decreasing ejection fraction (FIG. 9; Table 7). The difference in the incidence of the primary composite endpoint increased disproportionately between the placebo and omecamtiv mecarbil treatment groups with low ejection fraction (FIG. 10A), such that the absolute risk reduction with omecamtiv mecarbil increased progressively with decreasing ejection fraction (FIG. 10B). In the lowest ejection fraction quartile, omecamtiv mecarbir resulted in an absolute reduction of 7.4 events / 100 patient-years, with the number needed to treat to prevent an event being 11.8 patients at 3 years (Table 7).
[0222] The beneficial effect of treatment with omecamtiv mecarbil on the primary outcome was mainly driven by a significant reduction in heart failure events, with ejection fraction being an important modifier of this treatment effect (interaction by ejection fraction quartiles p=0.004, interaction by ejection fraction as a continuous variable p=0.001; Table 7). Ejection fraction showed a similar modifying effect on the progressive reduction in heart failure hospitalizations with omecamtiv mecarbil (interaction by ejection fraction quartiles p=0.004, interaction by ejection fraction as a continuous variable p=0.001; Figure 11A; Table 7). Consistent with the primary composite endpoint, the incidence of hospitalizations due to heart failure increased with decreasing ejection fraction in both placebo- and omecamtiv mecarbil-treated patients (Figure 11B), but was significantly affected by treatment with omecamtiv mecarbil, showing a progressively greater absolute decrease with decreasing ejection fraction. Ejection fraction similarly significantly modified the treatment of the effect of omecamtiv mecarbil on total heart failure events and hospitalizations (interaction p=0.006 and 0.009, respectively; Table 20). Omecamtiv mecarbil had no overall effect on cardiovascular death, either in the overall population or as a function of baseline ejection fraction (interaction by ejection fraction quartile p=0.14; FIG. 12A, Table 7). As expected, the incidence of cardiovascular death increased equally in both the placebo and omecamtiv mecarbil groups with decreasing ejection fraction (FIG. 12B, Table 7). Similarly, there was no effect of omecamtiv mecarbil on all-cause mortality (Table 7). The proportional hazards assumption was assessed for all hazard ratios presented in Table 2 by tests of Schoenfeld residuals. No significant violations were detected (all p>0.2). [Table 10]
[0223] Other outcomes and safety of omecamtiv mecarbil by ejection fraction Despite the reduction in heart failure events with omecamtiv mecarbil, there was no consistent beneficial effect on symptoms as a function of EF assessed by the KCCQ-TSS in subjects enrolled from either the inpatient or outpatient setting. However, there was a greater reduction in NT-proBNP with omecamtiv mecarbil in patients with low ejection fraction, such that the lowest EF quartile showed a 22% reduction (p<0.001), while the highest EF quartile showed only a 3% change (p=0.54; interaction p<0.001) (Table 9). [Table 11]
[0224] Omecamtiv mecarbil treatment resulted in modest reductions in heart rate (treatment difference 1.1 to 1.9 bpm across EF quartiles) and increases in troponin I (median 3 to 5 ng / L across EF quartiles; limit of detection, 6 ng / L; upper limit of normal, 40 ng / L), which did not differ across EF quartiles. There were no significant effects on systolic blood pressure, serum potassium, or creatine compared with placebo across EF quartiles. Additionally, there were no significant differences in the incidence of adverse events between omecamtiv mecarbil and placebo treatment groups, except for a clear reduction in the incidence of adjudicated stroke in patients treated with omecamtiv mecarbil (Tables 10 and 23A).
[0225] Omecamtiv mecarbil provided similar benefits in patients with and without a history of stroke. Patients assigned to omecamtiv mecarbil had a significant reduction in time to first stroke event. A history of stroke was present in 754 (9.2%) participants, who were more likely to be older and non-white, have atrial fibrillation / flutter, hypertension, diabetes mellitus, or ischemic heart disease, have worse NYHA class and eGFR, and have higher baseline NT-proBNP or troponin. Patients with a history of stroke were more likely to benefit from omecamtiv mecarbil on the primary endpoint (HR 0.86; 95% CI 0.70, 1.07; p=0.18) than those without stroke (HR 0.93; 95% CI 0.87, 1.00; p=0.06). Multivariate predictors of the 194 concomitant first stroke events included non-white race, history of stroke or percutaneous coronary intervention (PCI), and elevated baseline troponin or systolic blood pressure (Table 24). Patients randomized to omecamtiv mecarbil had a significant 35% reduction in risk of first fatal or nonfatal stroke (Figure 24) and a 42% reduction in fatal stroke (HR: 0.56; 95% CI 0.31, 0.99; p=0.048). The effect of omecamtiv mecarbil on non-fatal and fatal stroke risk according to history of stroke is shown in Figure 25 (with history of stroke--HR: 0.23; 95% Cl 0.09, 0.56; p=0.001, and without history of stroke--HR: 0.78; 95% Cl 0.57, 1.06; p=0.11). The effect of omecamtiv mecarbil on non-fatal and fatal stroke risk according to history of atrial fibrillation is shown in Figure 26 (with history of atrial fibrillation--HR: 0.49; 95% Cl 0.32, 0.76; p=0.001, without history of atrial fibrillation--HR: 0.81; 95% Cl 0.55, 1.19; p=0.29). The effect of omecamtivmecarbil on new onset of atrial fibrillation / flutter is shown in Figure 27 (no AF / F at screening--HR: 0.70; 95% Cl 0.50, 0.99; p=0.044, and no history of AF / F--HR: 0.60; 95% Cl 0.37, 1.00; p=0.048).Omecamtiv mecarbil significantly reduced nonfatal and fatal stroke in patients with heart failure with reduced ejection fraction, associated with a significant reduction in new onset of atrial fibrillation. Characteristics by baseline stroke history are shown in Table 25. [Table 12] [Table 13] [Table 14] [Table 15-1] [Table 15-2]
[0226] The assessment of EF by quartile in the current analysis included subgroups of approximately 2,000 patients with 578–979 events in each quartile, which are themselves larger than in many studies. We support these findings with an analysis of ejection fraction as a continuous variable incorporating data from all 8,232 patients. Although the statistical analysis plan from GALACTIC-HF prespecified multiple subgroups for assessment and is subject to issues related to multiplicity testing, the p-value for the univariate interaction versus the treatment-covariate interaction was 0.004, making it highly unlikely to be due to chance. Furthermore, this effect modification has biological plausibility, and the study findings are internally consistent.
[0227] Patients with more advanced heart failure Statistical approach Appropriate summary statistics were used to evaluate baseline characteristics of patients classified as having more advanced HF compared to those without more advanced HF. Cox proportional hazards models and Kaplan-Meier curves were used to compare outcomes of patients with or without more advanced HF. Interaction terms were used to evaluate whether omecamtiv mecarbil had a different effect on outcomes in advanced HF status. Absolute event rates were described using rates per 100 patient-years. As a sensitivity analysis, event rates and treatment effects of omecamtiv mecarbil for patients with specific advanced HF criteria met and total number of criteria met were evaluated. For data on quality of life assessed by the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS), linear regression adjusted for baseline scores was used to compare the treatment effect of omecamtiv mecarbil with placebo. Descriptive statistics were used to summarize safety and tolerability data for patients with advanced HF versus those without advanced HF. A P value ≦0.05 was considered statistically significant for all analyses.
[0228] result Of patients enrolled in GALACTIC-HF, 2258 (27%) met specific criteria for more advanced HF, of whom 1106 were randomized to treatment with omecamtiv mecarbir and 1152 to placebo. Baseline characteristics stratified by patients with or without more advanced HF are shown in Table 11. [Table 16-1] [Table 16-2]
[0229] As expected, patients with more advanced HF had markers of more severe disease, including lower ejection fraction, increased NYHA class, higher NT-proBNP concentrations, lower systolic blood pressure, worse renal function, and worse quality of life as assessed by the KCCQ TSS. Patients with more advanced HF were less likely to be treated with renin-angiotensin-aldosterone system (RAAS) modulators and beta-blockers at baseline, but more likely to receive cardiac resynchronization therapy (CRT) or an implantable cardioverter defibrillator (ICD). Patients with more advanced HF were at significantly higher risk, with event rates in placebo-treated patients nearly double those in patients without more advanced HF for the primary endpoint (42.6 vs. 21.3 events / 100 patient-years), cardiovascular mortality (17.3 vs. 8.5 events / 100 patient-years), and all-cause mortality (21.7 vs. 11.9 events / 100 patient-years).
[0230] Efficacy and safety of omecamtiv mecarbil in more advanced heart failure Patients classified as having more advanced HF had a greater treatment benefit from omecamtiv mecarbil treatment than patients without more advanced HF. For the primary endpoint, patients with more advanced HF had a 20% risk reduction (HR=0.80, 95% CI 0.71-0.90), whereas patients with less advanced HF had no significant treatment benefit (HR=0.99. 95% CI 0.91-1.08, p-value for interaction=0.005). These results were similar for cardiovascular mortality in patients with more advanced HF (HR=0.88, 95% CI 0.75-0.1.03) compared with those without advanced HF (HR=1.10, 95% CI 0.97-1.25, p-value for interaction=0.028). Kaplan-Meier curves comparing patients with and without more advanced HF for each of these endpoints are shown in Figures 14A and 14B. As an additional sensitivity analysis, we evaluated the event rate and treatment effect of omecamtiv mecarbil based on which and how many progressive HF criteria were met (Figures 15A and 15B). The observed benefit of omecamtiv mecarbil was greatest in patients who met all three progressive HF criteria, which was also the group with the highest overall risk. The combination of a 20% reduction in relative risk reduction in the primary endpoint in the setting of high baseline risk translated into an absolute risk reduction of 8.3 events / 100 patient-years (NNT=12). These results were broadly consistent across a range of other secondary outcomes from the GALACTIC-HF trial, as shown in Table 12. For the KCCQ, we found no differential impact of advanced HF status on total symptom score (TSS) in advanced HF status (TSS increased by 1.1 for hospitalized patients and decreased by 1.7 for outpatients with advanced HF) compared to non-advanced HF (TSS increased by 3.3 for hospitalized patients and decreased by 0.2 for outpatients, p for interaction = 0.09).
[0231] Safety data for omecamtiv mecarbil versus placebo by progressive HF category are summarized in Table 13. [Table 17-1] [Table 17-2] [Table 18]
[0232] Patients with more advanced HF were more likely to have treatment-emergent serious adverse events than non-advanced patients, but these were similar between omecamtiv mecarbil treated patients (67%) and placebo (69%). There was no significant difference in serious adverse events related to ventricular tachyarrhythmias between omecamtiv mecarbil and placebo in patients with more advanced HF (7.9% for omecamtiv vs. 8.1% for placebo). In patients with more advanced HF, there were numerically more myocardial infarctions (3.8% vs. 2.5%, p=0.08) but fewer strokes (1.6% vs. 2.7%, p=0.08) with omecamtiv mecarbil compared with placebo. Data on tolerability and changes in biomarkers are shown in Table 4. Similar to the overall trial, treatment of more advanced HF patients with omecamtiv mecarbil did not result in changes in blood pressure, worsening of renal function, or worsening of potassium compared to placebo. Heart rate was slightly reduced with omecamtiv mecarbil compared to placebo (difference of 1.9 beats / min change from 0 to 24 weeks, p<0.001 for omecamtiv mecarbil vs. placebo). In the more advanced HF population, treatment with omecamtiv mecarbil was associated with significant reductions in NT-proBNP and small increases in circulating cardiac troponins (Table 14). [Table 19-1] [Table 19-2]
[0233] Effect of OM by baseline NT-ProBNP level Natriuretic peptides are important for understanding the pathophysiology of heart failure, its diagnosis, prognosis, and evaluation of treatment. Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a hallmark of heart failure with reduced ejection fraction (HFrEF), and high circulating levels of this and other natriuretic peptides are associated with higher rates of non-fatal and fatal outcomes. Conversely, pharmacological treatments that are effective in reducing the risk of hospitalization for worsening heart failure and the risk of death in HFrEF patients also reduce natriuretic peptides. Omecamtiv mecarbil, a newly developed treatment for HFrEF, directly enhances cardiac contractility by selectively binding to cardiac myosin, increasing the number of myosin heads (power generators) that bind to actin filaments and initiate the power stroke at the beginning of systole. In a phase 2 study of patients with HFrEF, both short-term intravenous and long-term oral treatment with omecamtiv mecarbil improved cardiac function, with the latter reducing left ventricular systolic and diastolic volumes, plasma natriuretic peptide concentrations, and heart rate over 20 weeks. As a result, we conducted the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure trial (GALACTIC-HF) to evaluate whether treatment with omecamtiv mecarbil improves outcomes in patients with HFrEF who were enrolled as outpatients or hospitalized patients with decompensated heart failure. At a median of 22 months, omecamtiv mecarbil reduced the risk of the primary composite outcome of worsening heart failure events or cardiovascular death by 8% (hazard ratio 0.92; 95% confidence interval, 0.86 to 0.99; P = 0.03). Prior to study completion, we pre-specified that the effect of randomized treatment would be examined by baseline NT-proBNP either below or above the median (≦median, >median) associated with the randomized setting (outpatient or inpatient) excluding individuals with atrial fibrillation / flutter (AF / F).Here, we report the effect of omecamtiv mecarbir according to baseline NT-proBNP levels in patients without AF / F and in the overall population. In addition, we describe the effect of omecamtiv mecarbir using NT-proBNP as a continuous and categorical measure, and describe the effect of omecamtiv mecarbir on NT-proBNP levels.
[0234] Measurement of NT-proBNP and cardiac troponin I NT-proBNP was measured at baseline and at weeks 2, 6, 24, 48, and 96 after randomization. Plasma NT-proBNP was measured in a central laboratory (Q Squared Solutions) using the Roche Elecsys NT-proBNP site-specific electrochemiluminescence immunoassay (analytical range 50–35,000 pg / mL).
[0235] statistical analysis The primary outcome was a composite of heart failure events or cardiovascular death, and the study was designed to provide 90% power to detect a hazard ratio of 0.8 for cardiovascular death, resulting in a sample size of approximately 8,000 patients. The study was event-driven with a target of approximately 1590 cardiovascular deaths. Efficacy analyses were performed according to randomized treatment group assignment (intention to treat) on the full analysis set including all randomized patients, except for 24 subjects from a single site who were excluded for violations of the standards for clinical trial conduct of medicines. Baseline characteristics were summarized as frequencies with percentages, means with standard deviations (SD), or medians with interquartile ranges. Differences in baseline characteristics were tested using the Cochran-Armitage trend test for categorical variables and analysis of variance tests for continuous variables. Differences between treatment groups in NT-proBNP at time points after randomization in surviving patients were analyzed using an analysis of covariance model with treatment group assignment as a fixed effect factor and baseline NT-proBNP as a covariate. Results of analysis of covariance are presented as least squares mean differences with corresponding 95% CI. Time-to-event data were evaluated using Cox proportional hazards models with Kaplan-Meier estimates and baseline hazards stratified by randomization setting and region, with treatment group and baseline eGFR as covariates. Safety analyses were performed in patients who underwent randomization and received at least one dose of omecamtiv mecarbil or placebo. All analyses were performed using STATA version 15.1 (College Station, TX) and SAS version 9.4 (SAS Institute, Cary, NC). A P value of 0.05 was considered statistically significant.
[0236] result Baseline NT-proBNP measurements were available for 8206 of 8232 randomized patients. Of these, 5971 patients had a baseline ECG and were free of AF / F. The median baseline NT-proBNP level (Q1, Q3) was 1675 (812-3579) pg / mL in patients without AF / F and 1998 (993-4079) pg / mL in all randomized patients.
[0237] Baseline characteristics by median baseline NT-proBNP concentration in participants without AF / F and in the overall population are shown in Table 15. [Table 20-1] [Table 20-2] [Table 20-3]
[0238] Compared with patients with NT-proBNP levels below the median (≤median), patients with NT-proBNP levels above the median (>median) were older, more often from Western Europe or Latin America, and less often from Asia. Participants with NT-proBNP levels above the median had a lower mean body mass index and lower eGFR (eGFR 60 mL / min / 1.73 m 2 Participants without AF / F who had NT-proBNP levels above the median were more likely to have diabetes and an ischemic etiology than those with NT-proBNP levels below the median (though a higher proportion of patients with NT-proBNP levels below the median), had lower systolic blood pressure but higher heart rate and troponin I. They were also more likely to have lower ejection fractions and significantly worse NYHA functional class and KCCQ-TSS. These differences were seen in both participants without AF / F and in the overall population. Some differences were seen only in patients without AF / F and not in the overall population. Participants without AF / F who had NT-proBNP levels above the median were more likely to have diabetes and an ischemic etiology than those with NT-proBNP levels below the median (though these differences were not significant in the overall population).
[0239] With regard to heart failure treatment, patients with NT-proBNP levels higher than the median were less likely to be treated with renin-angiotensin system blockers (including sacubitril-valsartan), mineralocorticoid receptor antagonists, and beta-blockers, but were more likely to be prescribed diuretics and digoxin (even in patients without AF / F) and to have an implanted cardiac device.
[0240] In general, these differences were also observed in patients with AF / F, regardless of whether they were enrolled as outpatients or inpatients.
[0241] Hospitalization and mortality outcomes associated with baseline NT-proBNP concentrations As shown by the placebo group comparisons in Table 16, event rates were higher in patients with NT-proBNP greater than the median compared with those with NT-proBNP at or below the median in participants without AF / F and in the overall population. When NT-proBNP was examined as a continuous variable, the primary endpoint rate rose sharply with increasing NT-proBNP concentrations (Figures 16A-16D and 17A-17D). A similar observation was made in patients with AF / F, regardless of whether they were enrolled as outpatients or inpatients.
[0242] Effect of omecamtivmecarbil on outcomes according to baseline NT-proBNP concentration Table 16 shows the effect of omecamtiv mecarbil on pre-specified morbidity and mortality endpoints by baseline NT-proBNP levels divided by pre-specified medians in patients without AF / F and in the overall study population. Further analyses of the effect of omecamtiv mecarbil, examining NT-proBNP as a continuous variable, are shown in (Figures 18A-18D and 19A-19D). [Table 21-1] [Table 21-2]
[0243] Primary composite outcome In patients without AF / F, compared with placebo, omecamtivmecarbil had more benefit in the primary endpoint in participants with NT-proBNP above the median (HR 0.81, 95% CI 0.73 to 0.90) than in those with NT-proBNP below the median (HR 0.94, 0.80 to 1.09); P for interaction = 0.035. A similar interaction was seen in the overall population: HR 0.88, 0.80 to 0.96 in patients with NT-proBNP above the median and 1.01, 0.90 to 1.15 in participants with NT-proBNP below the median; P for interaction = 0.095.
[0244] When NT-proBNP was examined as a continuous variable, the increasing beneficial effect of omecamtiv mecarbil with increasing NT-proBNP became more evident, as shown in Figures 18A-18D and 19A-19D.
[0245] Qualitatively similar findings were seen in participants enrolled in both outpatient and inpatient settings. A completely different pattern was observed in patients with baseline AF / F, particularly those with NT-proBNP levels below the median, with higher event rates in the omecamtiv mecarbil group compared with placebo.
[0246] Secondary outcomes Examination of secondary hospitalization and mortality outcomes in patients without AF / F suggested that the interaction between baseline NT-proBNP levels and the effect of omecamtiv mecarbil was more evident for heart failure hospitalization than for cardiovascular or all-cause mortality (Table 16 and Figures 18A-18D and 19A-19D). In participants without AF / F and with NT-proBNP greater than the median, omecamtiv mecarbil reduced both hospitalization and mortality, but the mortality benefit was lost when analyzing the entire population, due to the lack of effect of omecamtiv mecarbil in patients with AF / F. Even the larger benefit of omecamtiv mecarbil on heart failure hospitalization was attenuated by the addition of AF / F patients to the entire population.
[0247] Table 17 shows the effect of omecamtiv mecarbil on physiological measures and plasma biomarkers by baseline NT-proBNP levels split by median in patients without AF / F and in the overall study population. [Table 22-1] [Table 22-2]
[0248] Changes from baseline (t0) to 24 weeks of visits are presented. Omecamtiv mecarbil did not significantly affect systolic blood pressure in any subgroup, but significantly reduced it by 1-2 beats per minute in all four patient subgroups. Troponin I was also significantly increased with omecamtiv mecarbil, and at similar rates in all four patient subgroups. In contrast, as shown in more detail in Figures 20A-F, omecamtiv mecarbil only reduced NT-proBNP in patients whose baseline NT-proBNP values were greater than the median at baseline.
[0249] Safety outcomes The incidence of adverse events according to treatment assignment by NT-proBNP category is shown in Table 18. [Table 23-1] [Table 23-2]
[0250] When comparing placebo groups, no substantial differences were found in any adverse events in patients with baseline NT-proBNP concentrations greater than the median compared with those below the median.Similarly, there was no strong or consistent evidence that adverse events were more common with omecamtiv mecarbir compared with placebo in any of the four subgroups of patients.
[0251] In GALACTIC-HF, the benefit of omecamtiv mecarbir appeared to be greater in patients with higher baseline NT-proBNP levels, especially in patients without AF / F.
[0252] Effect of OM by baseline atrial fibrillation / flutter (AF / F) Atrial fibrillation is common in patients with heart failure and causes morbidity and mortality. Atrial fibrillation does not alter the therapeutic effect of renin-angiotensin-aldosterone inhibitors, which have been proven to be beneficial in heart failure, but it may alter the therapeutic effect of beta-blockers. Here, we report the effect of omecamtiv mecarbil according to baseline status in either patients without AF / F or those with AF / F. Further investigation of the use of digoxin in two subpopulations was also evaluated.
[0253] result Baseline AF / F determinations were available for 8232 randomized patients. Of these, 5987 patients did not have AF / F on the baseline ECG. Baseline characteristics by median baseline AF / F status for participants without AF / F and those with AF / F are presented in Table 19. [Table 24-1] [Table 24-2]
[0254] Figure 21A shows the frequency of AFF in patients with LVEF below 35%. AFF was observed to coincide with higher LVEF (but below 35%).
[0255] We assessed the impact of AFF on the effect of OM on primary and secondary outcomes in patients who received or did not receive digoxin. In one of 24 prespecified subgroups, patients with AFF (n=2245, 27%) were older, more likely to be randomized as hospitalized patients, less likely to have an ischemic etiology or history of myocardial infarction, worse NYHA class, worse quality of life, lower eGFR, and higher NT-proBNP at baseline. AFF at baseline was associated with a small increase in the adjusted risk of cardiovascular death or heart failure events (HR 1.17, 95% CI 1.09, 1.27). Using a multivariate covariate interaction model, the treatment effect of OM appeared to be modified by AFF (interaction p=0.012), with patients without AFF inducing a larger benefit (Figure 21B, upper panel). Furthermore, as shown in Figure 21B, the presence of AFF was found to modify the treatment effect of omecamtiv mecarbil considering cardiovascular (CV) death (interaction p=0.002) and all-cause mortality (interaction p<0.001), with patients without AFF deriving a greater benefit. However, as shown in Figure 21E, treatment with omecamtiv mecarbil resulted in a significant reduction in serious adverse events in patients with atrial fibrillation / flutter at baseline (interaction p=0.046), with the omecamtiv mecarbil-treated arm having 55 events per 2974 patients and the placebo arm having 78 events per 3013 patients over the course of the study. Treatment effect modification by AFF was significantly more pronounced in digoxin users than in non-users (p=0.004), with strong evidence of effect modification in digoxin users with AFF (p=0.001), and minimal evidence of effect modification in non-users or digoxin users without AFF (p=0.52) (Figure 21B, bottom panel). In Figure 21D, the effect of digoxin use (with or without digoxin) in conjunction with omecamtiv mecarbil for patients with and without AFF is shown for cardiovascular death, all-cause death, and heart failure hospitalization.
[0256] Baseline atrial fibrillation or flutter modified the treatment effect of omecamtiv mecarbir, even after multivariate adjustment, with greater benefit observed in patients without AFF. Treatment effect modification by AFF was concentrated in patients using digoxin for AFF, with minimal evidence of effect modification in non-users of AFF. Digoxin did not modify the treatment effect of omecamtiv mecarbir in patients without AFF.
[0257] At 6 weeks, omecamtiv mecarbir PK values were similar in patients with and without digoxin (median 286 vs. 280 ng / ml, p=0.78). In patients with known digoxin dose, digoxin dose was similar in both treatment groups (0.12 mg vs. 0.12 mg, p=0.85) and in patients with and without baseline AFF (.12 mg vs. .12 mg, p=0.44). In patients with baseline AFF receiving omecamtiv mecarbir, troponin I did not increase at week 6 in patients with digoxin (+29%, +21% to +38%) vs. patients not receiving digoxin (+45%, +38% to 53%) (p=0.026).
[0258] Figures 21F and 21G show data from a study evaluating any drug-drug interactions between digoxin and omecamtiv mecarbil, which show the PK values of digoxin.
[0259] Patients with atrial fibrillation / flutter at baseline were less likely to benefit from OM than those without AFF, but this effect modification appeared to be caused by the use of digoxin in those patients, suggesting that the combination of AFF and digoxin is a potential risk factor when considering OM.
[0260] As shown in Table 21, among patients with EF≦30%, no AFF, and not taking digoxin at baseline, OM provided significant clinical benefit and reduced resource utilization. [Table 25]
[0261] Effect of OM on baseline systolic blood pressure (SBP) Systolic blood pressure (SBP) is the primary predictor of outcome in patients with heart failure and reduced ejection fraction (HFrEF). Omecamtiv mecarbil improved direct cardiac function and reduced the primary composite endpoint of episodes of worsening HF (emergency department visit, emergency department visit, or hospitalization) or cardiovascular death in the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure trial (GALACTIC-HF). This trial provided data on the efficacy and tolerability of omecamtiv mecarbil according to baseline SBP values. In contrast to other HFrEF treatments, which may not be tolerated in patients with low baseline BP (e.g., <100 mmHg), this study was able to enroll patients with an SBP of 85 mmHg or higher at baseline.
[0262] result The 8232 randomized patients were subdivided according to baseline SBP: <100 mmHg (n = 1473), 101-110 mmHg (n = 1734), 111-120 mmHg (n = 1824), 121-130 mmHg (n = 1627), and >130 mmHg (n = 1574). Significant differences were found between these subgroups with regard to several baseline characteristics. The primary composite endpoint occurred in 715 (48.5%), 682 (39.3%), 679 (37.2%), 556 (34.2%), and 498 (31.6%) patients in each SBP subgroup, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the treatment effect on the primary outcome were 0.81, 0.70-0.94; 0.88, 0.76-1.03; 1.03, 0.88-1.19; 0.87, 0.73-1.03; and 1.07, 0.90-1.28, respectively, in each SBP subgroup. When examined as a continuous variable, baseline SBP had a linear inverse correlation with the rate of major events and a linear direct correlation with the treatment effect (Figures 23A and 23B). No significant changes in SBP and differences in adverse events with omecamtiv mecarbil compared with placebo occurred during follow-up in each subgroup.
[0263] Omecamtiv mecarbil did not change SBP from baseline and was well tolerated regardless of baseline SBP, including in patients with low baseline blood pressure (<100 mmHg). Use of other HFrEF treatments may not be tolerated or may be associated with additional costs of increased adverse events or worsening renal function. Compared with placebo, omecamtiv mecarbil tended to have a greater effect on the primary outcome in patients with low baseline SBP (≤100 mmHg).
[0264] The effects of food Administration of OM to healthy subjects with a high-fat, high-calorie meal had clinically significant effects on systemic exposure.
[0265] distribution OM was observed to bind moderately to plasma proteins (81.5%), and protein binding was independent of drug concentration up to 4000 ng / mL. After a single dose of 35 mg radiolabeled OM in healthy subjects, the blood-to-plasma ratio of total radioactivity was approximately 0.4, indicating that radioactivity was not disproportionately distributed to blood components. The volume of distribution at steady state was approximately 4.8-6.6 L / kg.
[0266] discharge The clearance of OM after oral administration was mainly due to metabolism in the liver. The total systemic clearance was 11.7 L / h, and the mean renal clearance was 1 L / h, accounting for less than 10% of the total systemic clearance. The median half-life of OM was found to be approximately 23-32 hours in patients with heart failure. OM was observed to be extensively metabolized in the liver by multiple metabolic pathways, including CYP3A4 and CYP2D6. After oral administration of radiolabeled OM to healthy subjects, approximately 49% of the administered dose was excreted in the urine (mainly as metabolites with 8% of the parent compound recovered) and 38% in the feces (mainly as unchanged drug).
[0267] Patients with liver disorders The pharmacokinetics of a single 25 mg dose of OM was evaluated in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. The pharmacokinetics (Cmax and AUC) of OM in patients with mild or moderate hepatic impairment were similar to those in patients with normal hepatic function.
[0268] Drug interactions - effects of other drugs on the pharmacokinetics of OM OM has been found to be metabolized in vitro by multiple CYP enzymes, including CYP3A4 and CYP2D6. It is a substrate of P-gp and BCRP. OM may be administered with drugs that are inhibitors or inducers of CYP3A4, CYP2D6, P-gp, or BCRP. The effect of co-administered drugs on OM plasma exposure is shown in Table 22. [Table 26]
[0269] Drug interactions – Effect of OM on the pharmacokinetics of other drugs In vitro, OM has been found to be an inducer of P-gp, BCRP, MATE1, MATE2-K, CYP2C8, and CYP3A4. Clinical studies and results of physiologically based pharmacokinetic modeling indicate that OM is a weak inhibitor of CYP2C8 and BCRP and a weak inducer of CYP3A4. OM may be administered with drugs that are substrates of CYP3A4, CYP2C8, P-gp, or BCRP. A summary of the results of the clinical studies is presented in Table 23. [Table 27]
[0270] All references cited in this specification, including publications, patent applications, and patents, are hereby incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.
[0271] In describing the present invention (particularly in relation to the claims), the use of the terms "a" and "an" and "the" and "at least one" and similar referents should be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term "at least one" preceding a list of one or more items (e.g., "at least one of A and B") should be construed to mean one item selected from the listed items (A or B), or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" should be construed as open-ended terms (i.e., meaning "including but not limited to"), unless otherwise indicated herein or clearly contradicted by context. The recitation of ranges of values herein is intended only to serve as a shorthand method of referring individually to each individual value contained within the range, unless otherwise indicated herein, and each individual value is incorporated herein as if it were individually set forth herein. All of the methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary terms (e.g., "such as") presented herein is intended merely to facilitate understanding of the invention, and does not limit the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0272] References Ahmad T, Miller PE, McCullough M, et al. Why has positive inotropy failed in chronic heart failure?Lessons from prior inotrope trials.Eur J Heart Fail 2019;21:1064-78. Psotka MA,Gottlieb SS,Francis GS,et al.Cardiac Calcitropes,Myotropes,and Mitotropes.J Am Coll Cardiol 2019;73:2345-53. Malik FI,Hartman JJ,Elias KA,et al.Cardiac myosin activation:a potential therapeutic approach for systolic heart failure.Science 2011;331:1439-43. Psotka MA,Teerlink JR.Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.Handb Exp Pharmacol 2017;243:465-90. Planelles-Herrero VJ,Hartman JJ,Robert-Paganin J,Malik FI,Houdusse A.Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.Nat Commun 2017;8:190. Teerlink JR,Clarke CP,Saikali KG,et al.Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator,omecamtiv mecarbil:a first-in-man study.Lancet 2011;378:667-75. Cleland JG,Teerlink JR,Senior R,et al.The effects of the cardiac myosin activator,omecamtiv mecarbil,on cardiac function in systolic heart failure:a double-blind,placebo-controlled,crossover,dose-ranging phase 2 trial.Lancet 2011;378:676-83. Teerlink JR,Felker GM,McMurray JJ,et al.Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure:The ATOMIC-AHF Study.J Am Coll Cardiol 2016;67:1444-55. Teerlink JR,Felker GM,McMurray JJ,et al.Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure(COSMIC-HF):a phase 2,pharmacokinetic,randomised,placebo-controlled trial.Lancet 2016;388:2895-903. Teerlink JR,Diaz R,Felker GM,et al.Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction:Rationale and Design of GALACTIC-HF.JACC Heart Fail 2020;8:329-40. Hicks KA,Mahaffey KW,Mehran R,et al.2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.J Am Coll Cardiol 2018;71:1021-34. Haybittle JL.Repeated assessment of results in clinical trials of cancer treatment.Br J Radiol 1971;44:793-7. Peto R,Pike MC,Armitage P,et al.Design and analysis of randomized clinical trials requiring prolonged observation of each patient.I.Introduction and design.Br J Cancer 1976;34:585-612. Hardy RJ,Thompson SG.A likelihood approach to meta-analysis with random effects.Stat Med 1996;15:619-29. Teerlink JR,Diaz R,Felker GM,et al.Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction,GALACTIC-HF:Baseline Characteristics and Comparison with Contemporary Clinical Trials.Eur J Heart Fail 2020. Benjamini Y,Hochberg Y.Controlling the False Discovery Rate:A Practical and Powerful Approach to Multiple Testing.J R Statist Soc B 1995;57:289-300. Shen YT,Malik FI,Zhao X,et al.Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.Circ Heart Fail 2010;3:522-7. Kramer DG,Trikalinos TA,Kent DM,Antonopoulos GV,Konstam MA,Udelson JE.Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction:a meta-analytic approach.J Am Coll Cardiol 2010;56:392-406. Wessler BS,McCauley M,Morine K,Konstam MA,Udelson JE.Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.Eur J Heart Fail 2019;21:613-20. Vaduganathan M,Claggett B,Packer M,et al.Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.JACC Heart Fail 2018;6:564-9. Butler J,Khan MS,Mori C,et al.Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.Eur J Heart Fail 2020;22:999-1005. Tahhan AS,Vaduganathan M,Greene SJ,et al.Enrollment of Older Patients,Women,and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials:A Systematic Review.JAMA Cardiol 2018;3:1011-9. McMurray JJV,Solomon SD,Inzucchi SE,et al.Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med 2019;381:1995-2008. Packer M,Anker SD,Butler J,et al.Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.N Engl J Med 2020;383:1413-24. Fang JC,Ewald GA,Allen LA,Butler J,Westlake Canary CA,Colvin-Adams M,Dickinson MG,Levy P,Stough WG,Sweitzer NK,Teerlink JR,Whellan DJ,Albert NM,Krishnamani R,Rich MW,Walsh MN,Bonnell MR,Carson PE,Chan MC,Dries DL,Hernandez AF,Hershberger RE,Katz SD,Moore S,Rodgers JE,Rogers JG,Vest AR,Givertz MM and Heart Failure Society of America Guidelines C.Advanced(stage D)heart failure:a statement from the Heart Failure Society of America Guidelines Committee.Journal of cardiac failure.2015;21:519-34. Crespo-Leiro MG,Metra M,Lund LH,Milicic D,Costanzo MR,Filippatos G,Gustafsson F,Tsui S,Barge-Caballero E,De Jonge N,Frigerio M,Hamdan R,Hasin T,Hulsmann M,Nalbantgil S,Potena L,Bauersachs J,Gkouziouta A,Ruhparwar A,Ristic AD,Straburzynska-Migaj E,McDonagh T,Seferovic P and Ruschitzka F.Advanced heart failure:a position statement of the Heart Failure Association of the European Society of Cardiology.European journal of heart failure.2018;20:1505-1535. Writing Committee M,Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE,Jr.,Drazner MH,Fonarow GC,Geraci SA,Horwich T,Januzzi JL,Johnson MR,Kasper EK,Levy WC,Masoudi FA,McBride PE,McMurray JJ,Mitchell JE,Peterson PN,Riegel B,Sam F,Stevenson LW,Tang WH,Tsai EJ,Wilkoff BL and American College of Cardiology Foundation / American Heart Association Task Force on Practice G.2013 ACCF / AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines.Circulation.2013;128:e240-327. Metra M,Ponikowski P,Dickstein K,McMurray JJ,Gavazzi A,Bergh CH,Fraser AG,Jaarsma T,Pitsis A,Mohacsi P,Bohm M,Anker S,Dargie H,Brutsaert D,Komajda M and Heart Failure Association of the European Society of C.Advanced chronic heart failure:A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.European journal of heart failure.2007;9:684-94. Allen LA,Stevenson LW,Grady KL,Goldstein NE,Matlock DD,Arnold RM,Cook NR,Felker GM,Francis GS,Hauptman PJ,Havranek EP,Krumholz HM,Mancini D,Riegel B,Spertus JA,American Heart A,Council on Quality of C,Outcomes R,Council on Cardiovascular N,Council on Clinical C,Council on Cardiovascular R,Intervention,Council on Cardiovascular S and Anesthesia.Decision making in advanced heart failure:a scientific statement from the American Heart Association.Circulation.2012;125:1928-52. Allen LA,Fonarow GC,Grau-Sepulveda MV,Hernandez AF,Peterson PN,Partovian C,Li SX,Heidenreich PA,Bhatt DL,Peterson ED,Krumholz HM and American Heart Association’s Get With The Guidelines Heart Failure I.Hospital variation in intravenous inotrope use for patients hospitalized with heart failure:insights from Get With The Guidelines.Circ Heart Fail.2014;7:251-60. Nizamic T,Murad MH,Allen LA,McIlvennan CK,Wordingham SE,Matlock DD and Dunlay SM.Ambulatory Inotrope Infusions in Advanced Heart Failure:A Systematic Review and Meta-Analysis.JACC Heart failure.2018;6:757-767. Teerlink JR,Clarke CP,Saikali KG,Lee JH,Chen MM,Escandon RD,Elliott L,Bee R,Habibzadeh MR,Goldman JH,Schiller NB,Malik FI and Wolff AA.Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator,omecamtiv mecarbil:a first-in-man study.Lancet.2011;378:667-75. Cleland JG,Teerlink JR,Senior R,Nifontov EM,Mc Murray JJ,Lang CC,Tsyrlin VA,Greenberg BH,Mayet J,Francis DP,Shaburishvili T,Monaghan M,Saltzberg M,Neyses L,Wasserman SM,Lee JH,Saikali KG,Clarke CP,Goldman JH,Wolff AA and Malik FI.The effects of the cardiac myosin activator,omecamtiv mecarbil,on cardiac function in systolic heart failure:a double-blind,placebo-controlled,crossover,dose-ranging phase 2 trial.Lancet.2011;378:676-83. Teerlink JR,Felker GM,McMurray JJ,Solomon SD,Adams KF,Jr.,Cleland JG,Ezekowitz JA,Goudev A,Macdonald P,Metra M,Mitrovic V,Ponikowski P,Serpytis P,Spinar J,Tomcsanyi J,Vandekerckhove HJ,Voors AA,Monsalvo ML,Johnston J,Malik FI,Honarpour N and Investigators C-H.Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure(COSMIC-HF):a phase 2,pharmacokinetic,randomised,placebo-controlled trial.Lancet.2016;388:2895-2903. Teerlink JR,Diaz R,Felker GM,McMurray JJV,Metra M,Solomon SD,Adams KF,Anand I,Arias-Mendoza A,Biering-Sorensen T,Bohm M,Bonderman D,Cleland JGF,Corbalan R,Crespo-Leiro MG,Dahl,Cheverstrom,Filipparia JC,JLE G,Fonseca C,Goncalvesova E,Goudev AR,Howlett JG,Lanfear DE,Li J,Lund M,Macdonald P,Mareev V,Momomura SI,O'Meara E,Parkhomenko A,Ponikowski P,Ramires FJA,Serpytis P,Sliwa J,Sutersanyi,TM J,Vandekerckhove H,Vinereanu D,Voors AA,Yilmaz MB,Zannad F,Sharpsten L,Legg JC,Varin C,Honarpour N,Abbasi SA,Malik FI,Kurtz CE and Investigators GH.Cardiac Myosin Activation with Omecamtiv Mecardia in Heart Failure JN. Med.2020. Teerlink JR,Diaz R,Felker GM,McMurray JJV,Metra M,Solomon SD,Adams KF,Anand I,Arias-Mendoza A,Biering-Sorensen T,Bohm M,Bonderman D,Cleland JGF,Corbalan R,Crespo-Leiro MG,Dahlstrom U,Eng Correa,LEF JC,Filippatos G,Fonseca C,Goncalvesova E,Goudev AR,Howlett JG,Lanfear DE,Lund M,Macdonald P,Mareev V,Momomura SI,O'Meara E,Parkhomenko A,Ponikowski P,Ramires FJA,Serpytis P,Sliwa, JS,Tocspinsa,TM J,Vandekerckhove H,Vinereanu D,Voors AA,Yilmaz MB,Zannad F,Sharpsten L,Legg JC,Abbasi SA,Varin C,Malik FI,Kurtz CE and Investigators GH. contemporary clinical trials.European journal of heart failure.2020;22:2160-2171. Teerlink JR,Diaz R,Felker GM,McMurray JJV,Metra M,Solomon SD,Legg JC,Buchele G,Varin C,Kurtz CE,Malik FI and Honarpour N.Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction:Rationale and Design of GALACTIC-HF.JACC Heart failure.2020;8:329-340. Unroe KT,Greiner MA,Hernandez AF,Whellan DJ,Kaul P,Schulman KA,Peterson ED and Curtis LH.Resource Use in the Last 6 Months of Life Among Medicare Beneficiaries With Heart Failure,2000-2007.Archives of internal medicine.2011;171:196-203. Stewart GC,Kittleson MM,Patel PC,Cowger JA,Patel CB,Mountis MM,Johnson FL,Guglin ME,Rame JE,Teuteberg JJ and Stevenson LW.INTERMACS(Interagency Registry for Mechanically Assisted Circulatory Support)Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.Circ Heart Fail.2016;9. Lee DS,Tu JV,Juurlink DN,Alter DA,Ko DT,Austin PC,Chong A,Stukel TA,Levy D and Laupacis A.Risk-treatment mismatch in the pharmacotherapy of heart failure.JAMA.2005;294:1240-7. Ammar KA,Jacobsen SJ,Mahoney DW,Kors JA,Redfield MM,Burnett JC and Rodeheffer RJ.Prevalence and Prognostic Significance of Heart Failure Stages.Circulation.2007;115:1563-1570. Mann DL,Greene SJ,Givertz MM,Vader JM,Starling RC,Ambrosy AP,Shah P,McNulty SE,Mahr C,Gupta D,Redfield MM,Lala A,Lewis GD,Mohammed SF,Gilotra NA,Devore AD,Gorodeski EZ,Desvigne-Nickens P,Hernandez AF and Braunwald E.Sacubitril / Valsartan in Advanced Heart Failure With Reduced Ejection Fraction.JACC:Heart Failure.2020;8:789-799. Packer M,Bristow MR,Cohn JN,Colucci WS,Fowler MB,Gilbert EM,Shusterman NH and The USCHFSG.The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure.N Engl J Med.1996;334:1349-1355. Pitt B,Zannad F,Remme WJ,Cody R,Castaigne A,Perez A,Palensky J and Wittes J.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators.N Engl J Med.1999;341:709-17. Metra M,Eichhorn E,Abraham WT,Linseman J,Bohm M,Corbalan R,DeMets D,De Marco T,Elkayam U,Gerber M,Komajda M,Liu P,Mareev V,Perrone SV,Poole-Wilson P,Roecker E,Stewart J,Swedberg K,Tendera M,Wiens B,Bristow MR and Investigators E.Effects of low-dose oral enoximone administration on mortality,morbidity,and exercise capacity in patients with advanced heart failure:the randomized,double-blind,placebo-controlled,parallel group ESSENTIAL trials.Eur Heart J.2009;30:3015-26. Psotka MA,Gottlieb SS,Francis GS,et al.Cardiac Calcitropes,Myotropes,and Mitotropes.J Am Coll Cardiol 2019;73:2345-2353. Malik FI,Hartman JJ,Elias KA,et al.Cardiac myosin activation:a potential therapeutic approach for systolic heart failure.Science 2011;331:1439-43. Psotka MA,Teerlink JR.Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.Handb Exp Pharmacol 2017;243:465-490. Planelles-Herrero VJ,Hartman JJ,Robert-Paganin J,Malik FI,Houdusse A.Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.Nat Commun 2017;8:190. Teerlink JR,Felker GM,McMurray JJ,et al.Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure(COSMIC-HF):a phase 2,pharmacokinetic,randomised,placebo-controlled trial.Lancet 2016;388:2895-2903. Biering-Sorensen T,Minamisawa M,Claggett B,et al.Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure:The COSMIC-HF Trial.Circ Heart Fail 2020;13:e008007. Teerlink JR,Diaz R,Felker GM,et al.Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction:GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.Eur J Heart Fail 2020;22:2160-2171. Teerlink JR,Diaz R,Felker GM,et al.Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.N Engl J Med 2021;384:105-116. Teerlink JR,Diaz R,Felker GM,et al.Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction:Rationale and Design of GALACTIC-HF.JACC Heart Fail 2020;8:329-340. Hicks KA,Mahaffey KW,Mehran R,et al.2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.J Am Coll Cardiol 2018;71:1021-1034. Ahmad T,Miller PE,McCullough M,et al.Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.Eur J Heart Fail 2019;21:1064-1078. Teerlink JR,Clarke CP,Saikali KG,et al.Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator,omecamtiv mecarbil:a first-in-man study.Lancet 2011;378:667-75. Cleland JG,Teerlink JR,Senior R,et al.The effects of the cardiac myosin activator,omecamtiv mecarbil,on cardiac function in systolic heart failure:a double-blind,placebo-controlled,crossover,dose-ranging phase 2 trial.Lancet 2011;378:676-83. Teerlink JR,Felker GM,McMurray JJ,et al.Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure:The ATOMIC-AHF Study.J Am Coll Cardiol 2016;67:1444-55. Cleland JGF,Bunting KV,Flather MD,et al.Beta-blockers for heart failure with reduced,mid-range,and preserved ejection fraction:an individual patient-level analysis of double-blind randomized trials.Eur Heart J 2018;39:26-35. Solomon SD,Claggett B,Desai AS,et al.Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril / Valsartan(LCZ696)in Heart Failure with Reduced Ejection Fraction:The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure(PARADIGM-HF)Trial.Circ Heart Fail 2016;9:e002744. Solomon SD,Vaduganathan M,B LC,et al.Sacubitril / Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.Circulation 2020;141:352-361. Dewan P,Solomon SD,Jhund PS,et al.Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.Eur J Heart Fail 2020;22:1247-1258. Center for Drug Evaluation and Research,Food and Drug Administration.Integrated Review,Application Number 214377Orig1s000,NDA 214377 Vericiguat.2021. Solomon SD,Anavekar N,Skali H,et al.Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.Circulation 2005;112:3738-44. Ibrahim NE,Burnett JC Jr,Butler J,Camacho A,Felker GM,Fiuzat M,O’Connor C,Solomon SD,Vaduganathan M,Zile MR,Januzzi JL Jr.Natriuretic Peptides as Inclusion Criteria in Clinical Trials:A JACC:Heart Failure Position Paper.JACC Heart Fail.2020 May;8(5):347-358. Burnett JC Jr.Atrial Natriuretic Peptide,Heart Failure and the Heart as an Endocrine Organ.Clin Chem.2019 Dec;65(12):1602-1603. Mueller C,McDonald K,de Boer RA,Maisel A,Cleland JGF,Kozhuharov N,Coats AJS,Metra M,Mebazaa A,Ruschitzka F,Lainscak M,Filippatos G,Seferovic PM,Meijers WC,Bayes-Genis A,Mueller T,Richards M,Januzzi JL Jr;Heart Failure Association of the European Society of Cardiology.Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.Eur J Heart Fail.2019 Jun;21(6):715-731. Wessler BS,McCauley M,Morine K,Konstam MA,Udelson JE.Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.Eur J Heart Fail.2019 May;21(5):613-620. Troughton RW,Frampton CM,Brunner-La Rocca HP,Pfisterer M,Eurlings LW,Erntell H,Persson H,O’Connor CM,Moertl D,Karlstrom P,Dahlstrom U,Gaggin HK,Januzzi JL,Berger R,Richards AM,Pinto YM,Nicholls MG.Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization:an individual patient meta-analysis.Eur Heart J.2014 Jun 14;35(23):1559-67. Vaduganathan M,Claggett B,Packer M,McMurray JJV,Rouleau JL,Zile MR,Swedberg K,Solomon SD.Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.JACC Heart Fail.2018 Jul;6(7):564-569. Zile MR,Claggett BL,Prescott MF,McMurray JJ,Packer M,Rouleau JL,Swedberg K,Desai AS,Gong J,Shi VC,Solomon SD.Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.J Am Coll Cardiol.2016 Dec 6;68(22):2425-2436. Malik FI,Hartman JJ,Elias KA,Morgan BP,Rodriguez H,Brejc K,Anderson RL,Sueoka SH,Lee KH,Finer JT,Sakowicz R,Baliga R,Cox DR,Garard M,Godinez G,Kawas R,Kraynack E,Lenzi D,Lu PP,Muci A,Niu C,Qian X,Pierce DW,Pokrovskii M,Suehiro I,Sylvester S,Tochimoto T,Valdez C,Wang W,Katori T,Kass DA,Shen YT,Vatner SF,Morgans DJ.Cardiac myosin activation:a potential therapeutic approach for systolic heart failure.Science.2011 Mar 18;331(6023):1439–43. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA,Malik FI.The effects of the cardiac myosin activator,omecamtiv mecarbil,on cardiac function in systolic heart failure:a double-blind,placebo-controlled,crossover,dose-ranging phase 2 trial.Lancet.2011 Aug 20;378(9792):676-83. Teerlink JR,Felker GM,McMurray JJV,Ponikowski P,Metra M,Filippatos GS,Ezekowitz JA,Dickstein K,Cleland JGF,Kim JB,Lei L,Knusel B,Wolff AA,Malik FI,Wasserman SM;ATOMIC-AHF Investigators.Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure:The ATOMIC-AHF Study.J Am Coll Cardiol.2016 Mar 29;67(12):1444-1455. Teerlink JR,Felker GM,McMurray JJ,Solomon SD,Adams KF Jr,Cleland JG,Ezekowitz JA,Goudev A,Macdonald P,Metra M,Mitrovic V,Ponikowski P,Serpytis P,Spinar J,Tomcsanyi J,Vandekerckhove HJ,Voors AA,Monsalvo ML,Johnston J,Malik FI,Honarpour N;COSMIC-HF Investigators.Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure(COSMIC-HF):a phase 2,pharmacokinetic,randomised,placebo-controlled trial.Lancet.2016 Dec 10;388(10062):2895-2903. Teerlink JR,Diaz R,Felker GM,McMurray JJV,Metra M,Solomon SD,Legg JC,Buchele G,Varin C,Kurtz CE,Malik FI,Honarpour N.Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction:Rationale and Design of GALACTIC-HF.JACC Heart Fail.2020 Apr;8(4):329-340. Teerlink JR,Diaz R,Felker GM,McMurray JJV,Metra M,Solomon SD,Adams KF,Anand I,Arias-Mendoza A,Biering-Sorensen T,Bohm M,Bonderman D,Cleland JGF,Corbalan R,Crespo-Leiro MG,Dahlstrom U,Eng Correa,LEF JC,Filippatos G,Fonseca C,Goncalvesova E,Goudev AR,Howlett JG,Lanfear DE,Lund M,Macdonald P,Mareev V,Momomura SI,O'Meara E,Parkhomenko A,Ponikowski P,Ramires FJA,Serpytis P,Sliwa, JS,Tocspinsa,TM J,Vandekerckhove H,Vinereanu D,Voors AA,Yilmaz MB,Zannad F,Sharpsten L,Legg JC,Abbasi SA,Varin C,Malik FI,Kurtz CE;GALACTIC-HF Investigators. comparison with contemporary clinical trials.Eur J Heart Fail.2020 Nov;22(11):2160-2171. Teerlink JR,Diaz R,Felker GM,McMurray JJV,Metra M,Solomon SD,Adams KF,Anand I,Arias-Mendoza A,Biering-Sorensen T,Bohm M,Bonderman D,Cleland JGF,Corbalan R,Crespo-Leiro MG,Dahl,Cheverstrom,Filipparia JC,JLE G,Fonseca C,Goncalvesova E,Goudev AR,Howlett JG,Lanfear DE,Li J,Lund M,Macdonald P,Mareev V,Momomura SI,O'Meara E,Parkhomenko A,Ponikowski P,Ramires FJA,Serpytis P,Sliwa J,Sutersanyi,TM J,Vandekerckhove H,Vinereanu D,Voors AA,Yilmaz MB,Zannad F,Sharpsten L,Legg JC,Varin C,Honarpour N,Abbasi SA,Malik FI,Kurtz CE;GALACTIC-HF Investigators.Cardiac Myosin Activation with Mecardia Failure in Heart Failure J.N. Med.2021 Jan 14;384(2):105-116. Grodin JL,Liebo MJ,Butler J,Metra M,Felker GM,Hernandez AF,Voors AA,McMurray JJ,Armstrong PW,O’Connor C,Starling RC,Troughton RW,Tang WHW.Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure:Insights From ASCEND-HF.J Card Fail.2019 Sep;25(9):703-711. Rorth R,Jhund PS,Yilmaz MB,Kristensen SL,Welsh P,Desai AS,Kober L,Prescott MF,Rouleau JL,Solomon SD,Swedberg K,Zile MR,Packer M,McMurray JJV.Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.Circ Heart Fail.2020 Feb;13(2):e006541. Kristensen SL,Mogensen UM,Jhund PS,Rorth R,Anand IS,Carson PE,Desai AS,Pitt B,Pfeffer MA,Solomon SD,Zile MR,Kober L,McMurray JJV.N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.Circ Heart Fail.2019 Mar;12(3):e005766. Kristensen SL,Jhund PS,Mogensen UM,Rorth R,Abraham WT,Desai A,Dickstein K,Rouleau JL,Zile MR,Swedberg K,Packer M,Solomon SD,Kober L,McMurray JJV;PARADIGM-HF and ATMOSPHERE Committees and Investigators.Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.Circ Heart Fail.2017 Oct;10(10):e004409. Loungani RS,Mentz RJ,Agarwal R,DeVore AD,Patel CB,Rogers JG,Russell SD,Felker GM.Biomarkers in Advanced Heart Failure:Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation.Circ Heart Fail.2020 Jul;13(7):e006840. Cui D,Liao Y,Li G,Chen Y.Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure:A Meta-analysis of Randomized Controlled Trials.Am J Cardiovasc Drugs.2021 Jan;21(1):73-81. Comin-Colet J,Manito N,Segovia-Cubero J,Delgado J,Garcia Pinilla JM,Almenar L,Crespo-Leiro MG,Sionis A,Blasco T,Pascual-Figal D,Gonzalez-Vilchez F,Lambert-Rodriguez JL,Grau M,Bruguera J;LION-HEART Study Investigators.Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure:the LION-HEART multicentre randomised trial.Eur J Heart Fail.2018 Jul;20(7):1128-1136. Najjar E,Stalhberg M,Hage C,Ottenblad E,Manouras A,Haugen Lofman I,Lund LH.Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.ESC Heart Fail.2018 Jun;5(3):302-308. Ezekowitz JA,O’Connor CM,Troughton RW,Alemayehu WG,Westerhout CM,Voors AA,Butler J,Lam CSP,Ponikowski P,Emdin M,Patel MJ,Pieske B,Roessig L,Hernandez AF,Armstrong PW.N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes:Vericiguat Heart Failure With Reduced Ejection Fraction Study.JACC Heart Fail.2020 Nov;8(11):931-939. Kotecha,D.et al.Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis.The Lancet,DECEMBER 20,2014,VOLUME 384,ISSUE 9961,p2235-2243.
Claims
1. 1. A pharmaceutical composition for use in a method for treating heart failure in a patient with a left ventricular ejection fraction (LVEF) of less than 35%, comprising omecamtiv mecarbil, or a hydrate, salt, or salt of the hydrate thereof.
2. 2. The pharmaceutical composition for use according to claim 1, wherein the patient's LVEF is less than 30%.
3. 2. The pharmaceutical composition for use according to claim 1, wherein the patient's LVEF is less than 28%.
4. 2. The pharmaceutical composition for use according to claim 1, wherein the patient's LVEF is less than 25%.
5. 2. The pharmaceutical composition for use according to claim 1, wherein the patient's LVEF is less than 22%.
6. A pharmaceutical composition for use according to any one of claims 1 to 5, wherein the patient does not exhibit atrial fibrillation or atrial flutter.
7. A pharmaceutical composition for use according to any one of claims 1 to 6, wherein the patient is not receiving digoxin.
8. 1. A pharmaceutical composition for use in a method for treating heart failure in a patient not exhibiting atrial fibrillation or atrial flutter, comprising omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
9. A pharmaceutical composition for use in a method for treating heart failure in a patient in need thereof, comprising omecamtiv mecarbil, or a hydrate, salt, or salt of the hydrate thereof, The patient has: i) heart failure classified as class III or IV as determined using the New York Heart Association (NYHA) classification; ii) progressive heart failure; and iii) pretreatment levels of NT-proBNP of at least 2,000 pg / mL A pharmaceutical composition for said use, comprising one or more of:
10. 10. The pharmaceutical composition for use according to claim 9, wherein the patient does not exhibit atrial fibrillation or atrial flutter.
11. 1. A pharmaceutical composition for use in a method for treating heart failure in a patient suffering from hypotension, comprising omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
12. The pharmaceutical composition for use according to claim 11, wherein the patient has a systolic blood pressure (SBP) of less than 100 mmHg.
13. 1. A pharmaceutical composition for use in a method for preventing stroke in a patient suffering from heart failure with reduced ejection fraction (HFrEF), comprising omecamtiv mecarbil, or a hydrate, salt, or salt of the hydrate thereof.
14. 14. The pharmaceutical composition for use according to claim 13, wherein the stroke is non-fatal.
15. 14. The pharmaceutical composition for use according to claim 13, wherein the stroke is fatal.
16. The pharmaceutical composition for use according to any one of claims 13 to 15, wherein the stroke is ischemic.
17. The pharmaceutical composition for use according to any one of claims 13 to 15, wherein the stroke is ischemic with hemorrhagic transformation.
18. The pharmaceutical composition for use according to any one of claims 13 to 15, wherein the stroke is hemorrhagic.
19. A pharmaceutical composition for use in a method for treating heart failure in a patient not receiving digoxin, comprising omecamtiv mecarbil, or a hydrate, salt, or salt of the hydrate thereof.
20. 20. The pharmaceutical composition for use according to any one of claims 1 to 19, characterized in that the omecamtiv mecarbir is administered orally, optionally the omecamtiv mecarbir is administered in a tablet.
21. A pharmaceutical composition for use according to any one of claims 1 to 20, comprising omecamtiv mecarbir dihydrochloride hydrate.
22. 22. The pharmaceutical composition for use according to any one of claims 1 to 21, wherein the omecamtiv mecarbil, or a hydrate, salt, or hydrate salt thereof is administered twice daily, optionally in a modified release matrix tablet, optionally wherein the omecamtiv mecarbil is administered in a dosage of 25 mg twice daily, 37.5 mg twice daily, or 50 mg twice daily.
23. The pharmaceutical composition for use according to claim 8, wherein the patient is not receiving digoxin.
